Aflatoxin Literature: Liver Cancer

 

 

Zheng CF, Zeng H, Wang J, Lin H, Feng XB, Chen JA, Qiu ZQ, Luo JH, Xu AW, Wang LQ, Tan Y, Chen S, Jiang P, Shu WQ. The association between aflatoxin exposure and primary hepatocellular carcinoma risks: a case-control study in Chongqing. Zhonghua Yu Fang Yi Xue Za Zhi. 2017 Jun 6;51(6):539-545. PMID: 28592100

Chu YJ, Yang HI, Wu HC, Liu J, Wang LY, Lu SN, Lee MH, Jen CL, You SL, Santella RM, Chen CJ. Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers. Int J Cancer. 2017 Aug 15;141(4):711-720. PMID: 28509392

Wu XM, Xi ZF, Liao P, Huang HD, Huang XY, Wang C, Ma Y, Xia Q, Yao JG, Long XD. Diagnostic and prognostic potential of serum microRNA-4651 for patients with hepatocellular carcinoma related to aflatoxin B1. Oncotarget. 2017 Mar 8. PMID: 28423689

Vartanian V, Minko IG, Chawanthayatham S, Egner PA, Lin YC, Earley LF, Makar R, Eng JR, Camp MT, Li L, Stone MP, Lasarev MR, Groopman JD, Croy RG, Essigmann JM, McCullough AK, Lloyd RS. NEIL1 protects against aflatoxin-induced hepatocellular carcinoma in mice. Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):4207-4212. PMID: 28373545

Zhang W, He H, Zang M, Wu Q, Zhao H, Lu LL, Ma P, Zheng H, Wang N, Zhang Y, He S, Chen X, Wu Z, Wang X, Cai J, Liu Z, Sun Z, Zeng YX, Qu C, Jiao Y. Genetic Features of Aflatoxin-Associated Hepatocellular Carcinoma. Gastroenterology. 2017 Jul;153(1):249-262.e2. PMID: 28363643

Narkwa PW, Blackbourn DJ, Mutocheluh M. Aflatoxin B1 inhibits the type 1 interferon response pathway via STAT1 suggesting another mechanism of hepatocellular carcinoma. Infect Agent Cancer. 2017 Mar 20;12:17. PMID: 28344639

Weng MW, Lee HW, Choi B, Wang HT, Hu Y, Mehta M, Desai D, Amin S, Zheng Y, Tang MS. AFB1 hepatocarcinogenesis is via lipid peroxidation that inhibits DNA repair, sensitizes mutation susceptibility and induces aldehyde-DNA adducts at p53 mutational hotspot codon 249. Oncotarget. 2017 Mar 14;8(11):18213-18226. PMID: 28212554

Adebayo Michael AO, Ahsan N, Zabala V, Francois-Vaughan H, Post S, Brilliant KE, Salomon AR, Sanders JA, Gruppuso PA. Proteomic analysis of laser capture microdissected focal lesions in a rat model of progenitor marker-positive hepatocellular carcinoma. Oncotarget. 2017 Apr 18;8(16):26041-26056. PMID: 28199961

Ledda C, Loreto C, Zammit C, Marconi A, Fago L, Matera S, Costanzo V, Fuccio Sanzà G, Palmucci S, Ferrante M, Costa C, Fenga C, Biondi A, Pomara C, Rapisarda V. Non‑infective occupational risk factors for hepatocellular carcinoma: A review (Review). Mol Med Rep. 2017 Feb;15(2):511-533. PMID: 28000892

Wambui JM, Karuri EG, Ojiambo JA, Njage PM. Application of Probabilistic Modeling to Quantify the Reduction Levels of Hepatocellular Carcinoma Risk Attributable to Chronic Aflatoxins Exposure. Nutr Cancer. 2017 Jan;69(1):1-13. PMID: 27918845

Nishida N, Kudo M. Clinical Significance of Epigenetic Alterations in Human Hepatocellular Carcinoma and Its Association with Genetic Mutations. Dig Dis. 2016;34(6):708-713. PMID: 27750242

Marrone AK, Tryndyak V, Beland FA, Pogribny IP. MicroRNA Responses to the Genotoxic Carcinogens Aflatoxin B1 and Benzo[a]pyrene in Human HepaRG Cells. Toxicol Sci. 2016 Feb;149(2):496-502. PMID: 26609139

Qin H, Li H, Zhou X, Peng C, Tan H, Wang M. Effect of superoxide and inflammatory factor on aflatoxin B1 triggered hepatocellular carcinoma. Am J Transl Res. 2016 Sep 15;8(9):4003-4008. eCollection 2016. PMID: 27725881

Schulze K, Zucman-Rossi J. Translating the molecular diversity of hepatocellular carcinoma into clinical practice. Mol Cell Oncol. 2015 Sep 1;3(4):e1057316. PMID: 27652310

Shi J, He J, Lin J, Sun X, Sun F, Ou C, Jiang C. Distinct response of the hepatic transcriptome to Aflatoxin B1 induced hepatocellular carcinogenesis and resistance in rats. Sci Rep. 2016 Aug 22;6:31898. PMID: 27545718

Bai K, Cai Q, Jiang Y, Lv L. Coffee consumption and risk of hepatocellular carcinoma: a meta-analysis of eleven epidemiological studies. Onco Targets Ther. 2016 Jul 19;9:4369-75. PMID: 27499631

Yang C, Fu R, Zhuang Z, Wang S. Studies on the biological functions of CPS1 in AFB1 induced hepatocarcinogenesis. Gene. 2016 Oct 10;591(1):255-61. PMID: 27425868

Kucukcakan B, Hayrulai-Musliu Z. Challenging Role of Dietary Aflatoxin B1 Exposure and Hepatitis B Infection on Risk of Hepatocellular Carcinoma. Open Access Maced J Med Sci. 2015 Jun 15;3(2):363-9. PMID: 27275251

Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016 Apr 14;2:16018. PMID: 27158749

Rieswijk L, Claessen SM, Bekers O, van Herwijnen M, Theunissen DH, Jennen DG, de Kok TM, Kleinjans JC, van Breda SG. Aflatoxin B1 induces persistent epigenomic effects in primary human hepatocytes associated with hepatocellular carcinoma. Toxicology. 2016 Mar 28;350-352:31-9. PMID: 27153756

Kant R, Yen CH, Lu CK, Lin YC, Li JH, Chen YM. Identification of 1,2,3,4,6-Penta-O-galloyl-β-d-glucopyranoside as a Glycine N-Methyltransferase Enhancer by High-Throughput Screening of Natural Products Inhibits Hepatocellular Carcinoma. Int J Mol Sci. 2016 May 4;17(5). PMID: 27153064

Mazzanti R, Arena U, Tassi R. Hepatocellular carcinoma: Where are we? World J Exp Med. 2016 Feb 20;6(1):21-36. PMID: 26929917

Tognarelli J, Ladep NG, Crossey MM, Okeke E, Duguru M, Banwat E, Taylor-Robinson SD. Reasons why West Africa continues to be a hotbed for hepatocellular carcinoma. Niger Med J. 2015 Jul-Aug;56(4):231-5. PMID: 26759504

Maurya BK, Trigun SK. Fisetin Modulates Antioxidant Enzymes and Inflammatory Factors to Inhibit Aflatoxin-B1 Induced Hepatocellular Carcinoma in Rats. Oxid Med Cell Longev. 2016;2016:1972793. PMID: 26682000

Saleh DA, Amr S, Jillson IA, Wang JH, Crowell N, Loffredo CA. Preventing hepatocellular carcinoma in Egypt: results of a Pilot Health Education Intervention Study. BMC Res Notes. 2015 Aug 29;8:384. PMID: 26319021

Wang CH, Wey KC, Mo LR, Chang KK, Lin RC, Kuo JJ. Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma. Asian Pac J Cancer Prev. 2015;16(9):3595-604. PMID: 25987009

Aydın M, Aydın S, Bacanlı M, Başaran N. Aflatoxin levels in chronic hepatitis B patients with cirrhosis or hepatocellular carcinoma in Balıkesir, Turkey. J Viral Hepat. 2015 Nov;22(11):926-35. PMID: 25894298

Kar P. Risk factors for hepatocellular carcinoma in India. J Clin Exp Hepatol. 2014 Aug;4(Suppl 3):S34-42. PMID: 25755609

Singh KB, Maurya BK, Trigun SK. Activation of oxidative stress and inflammatory factors could account for histopathological progression of aflatoxin-B1 induced hepatocarcinogenesis in rat. Mol Cell Biochem. 2015 Mar;401(1-2):185-96. PMID: 25543524

Ladep NG, Lesi OA, Mark P, Lemoine M, Onyekwere C, Afihene M, Crossey MM, Taylor-Robinson SD. Problem of hepatocellular carcinoma in West Africa. World J Hepatol. 2014 Nov 27;6(11):783-92. PMID: 25429316

Yao JG, Huang XY, Long XD. Interaction of DNA repair gene polymorphisms and aflatoxin B1 in the risk of hepatocellular carcinoma. Int J Clin Exp Pathol. 2014 Aug 15;7(9):6231-44. PMID: 25337275

Chawanthayatham S, Thiantanawat A, Egner PA, Groopman JD, Wogan GN, Croy RG, Essigmann JM. Prenatal exposure of mice to the human liver carcinogen aflatoxin B1 reveals a critical window of susceptibility to genetic change. Int J Cancer. 2015 Mar 15;136(6):1254-62. PMID: 25070670

Qi LN, Bai T, Chen ZS, Wu FX, Chen YY, De Xiang B, Peng T, Han ZG, Li LQ. The p53 mutation spectrum in hepatocellular carcinoma from Guangxi, China : role of chronic hepatitis B virus infection and aflatoxin B1 exposure. Liver Int. 2015 Mar;35(3):999-1009. PMID: 24461059

Lai H, Mo X, Yang Y, He K, Xiao J, Liu C, Chen J, Lin Y. Association between aflatoxin B1 occupational airway exposure and risk of hepatocellular carcinoma: a case-control study. Tumour Biol. 2014 Oct;35(10):9577-84. PMID: 24961349

Johnson NM, Egner PA, Baxter VK, Sporn MB, Wible RS, Sutter TR, Groopman JD, Kensler TW, Roebuck BD. Complete protection against aflatoxin B(1)-induced liver cancer with a triterpenoid: DNA adduct dosimetry, molecular signature, and genotoxicity threshold. Cancer Prev Res (Phila). 2014 Jul;7(7):658-65. PMID: 24662598

Eaton DL, Schaupp CM. Of mice, rats, and men: could Nrf2 activation protect against aflatoxinheptocarcinogenesis in humans? Cancer Prev Res (Phila). 2014 Jul;7(7):653-7. PMID: 24934619

Liu YX, Long XD, Xi ZF, Ma Y, Huang XY, Yao JG, Wang C, Xing TY, Xia Q. MicroRNA-24 modulates aflatoxin B1-related hepatocellular carcinoma prognosis and tumorigenesis. Biomed Res Int. 2014;2014:482926. 2014 Apr 8. PMID: 24800232

Lv J, Yu YQ, Li SQ, Luo L, Wang Q. Aflatoxin B1 promotes cell growth and invasion in hepatocellular carcinoma HepG2 cells through H19 and E2F1. Asian Pac J Cancer Prev. 2014;15(6):2565-70. PMID: 24761865

Ou C, Zheng HP, Su JJ, Cao J, Li GJ, Li LQ. Effect of Ginkgo biloba extract on the expressions of Cox-2 and GST-Pi in rats with hepatocellular carcinoma risk. Afr Health Sci. 2014 Mar;14(1):37-48. PMID: 26060456

Adeleye AO, Ajiboye TO, Iliasu GA, Abdussalam FA, Balogun A, Ojewuyi OB, Yakubu MT. Phenolic extract of Dialium guineense pulp enhances reactive oxygen species detoxification in aflatoxin B₁ hepatocarcinogenesis. J Med Food. 2014 Aug;17(8):875-85. PMID: 24892362

Shen YH, Chen S, Peng YF, Shi YH, Huang XW, Yang GH, Ding ZB, Yi Y, Zhou J, Qiu SJ, Fan J, Ren N. Quantitative assessment of the effect of glutathione S-transferase genes GSTM1 and GSTT1 on hepatocellular carcinoma risk. Tumour Biol. 2014 May;35(5):4007-15. PMID: 24399650

Popp W, Gantumur T, Ross B, Zorigt K, Davaadorj D, Rossburg M, Sowa JP, Canbay A. Aflatoxin exposure may not play a role in liver cancer development in Mongolia. Digestion. 2014;89(4):268-71. PMID: 25011557

Chen JG, Egner PA, Ng D, Jacobson LP, Muñoz A, Zhu YR, Qian GS, Wu F, Yuan JM, Groopman JD, Kensler TW. Reduced aflatoxin exposure presages decline in liver cancer mortality in an endemic region of China. Cancer Prev Res (Phila). 2013 Oct;6(10):1038-45. PMID: 23963804

Qi LN, Li LQ, Chen YY, Chen ZH, Bai T, Xiang BD, Qin X, Xiao KY, Peng MH, Liu ZM, Liu TW, Qin X, Li S, Han ZG, Mo ZN, Santella RM, Winkler CA, O’Brien SJ, Peng T. Genome-wide and differential proteomic analysis of hepatitis B virus and aflatoxin B1 related hepatocellular carcinoma in Guangxi, China. PLoS One. 2013 Dec 31;8(12):e83465. PMID: 24391771

Bacigalupo ML, Manzi M, Rabinovich GA, Troncoso MF. Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma. World J Gastroenterol. 2013 Dec 21;19(47):8831-49. PMID: 24379606

Omar A, Abou-Alfa GK, Khairy A, Omar H. Risk factors for developing hepatocellular carcinoma in Egypt. Chin Clin Oncol. 2013 Dec;2(4):43. PMID: 25841922

Moudgil V, Redhu D, Dhanda S, Singh J. A review of molecular mechanisms in the development of hepatocellular carcinoma by aflatoxin and hepatitis B and C viruses. J Environ Pathol Toxicol Oncol. 2013;32(2):165-75. PMID: 24099430

Kew MC. Aflatoxins as a cause of hepatocellular carcinoma. J Gastrointestin Liver Dis. 2013 Sep;22(3):305-10. PMID: 24078988

Niu Y, Wu Z, Shen Q, Song J, Luo Q, You H, Shi G, Qin W. Hepatitis B virus X protein co-activates pregnane X receptor to induce the cytochrome P450 3A4 enzyme, a potential implication in hepatocarcinogenesis. Dig Liver Dis. 2013 Dec;45(12):1041-8. PMID: 23891548

Long XD, Zhao D, Wang C, Huang XY, Yao JG, Ma Y, Wei ZH, Liu M, Zeng LX, Mo XQ, Zhang JJ, Xue F, Zhai B, Xia Q. Genetic polymorphisms in DNA repair genes XRCC4 and XRCC5 and aflatoxin B1-related hepatocellular carcinoma. Epidemiology. 2013 Sep;24(5):671-81. PMID: 23788213

Mohd Redzwan S., Rosita Jamaluddin, Mohd Sokhini A. M., et al. Detection of serum AFB1-lysine adduct in Malaysia and its association with liver and kidney functions. International journal of hygiene and environmental health. 2013.

Magnussen Arvin, Parsi Mansour A.. Aflatoxins, hepatocellular carcinoma and public health. World journal of gastroenterology : WJG. 2013;19:1508–1512.

Hamid Abdu Selim S., Tesfamariam Isaias Goitom G., Zhang Yucheng, Zhang Zhen Gui G.. Aflatoxin B1-induced hepatocellular carcinoma in developing countries: Geographical distribution, mechanism of action and prevention. Oncology letters. 2013;5:1087–1092.

Carvalho Fernanda Magri M., Almeida Pereira Thiago, Gonçalves Patrícia Lofego L., Jarske Robson Dettmann D., Pereira Fausto Edmundo Lima E., Louro Iuri Drumond D.. Hepatocellular carcinoma and liver cirrhosis TP53 mutation analysis reflects a moderate dietary exposure to aflatoxins in Espírito Santo State, Brazil. Molecular biology reports. 2013.

Long Xi-Dai D., Zhao Dong, Wang Chao, et al. Genetic Polymorphisms in DNA Repair Genes XRCC4 and XRCC5 and Aflatoxin B1-related Hepatocellular Carcinoma. Epidemiology (Cambridge, Mass.). 2013.

Hamed Manal A., Ali Sanaa A.. Non-viral factors contributing to hepatocellular carcinoma. World journal of hepatology. 2013;5:311–322.

Ortiz-Cuaran Sandra, Villar Stephanie, Gouas Doriane, et al. Association between HBX status, aflatoxin-induced R249S TP53 mutation and risk of hepatocellular carcinoma in a case-control study from Thailand. Cancer letters. 2013;331:46–51.

Palliyaguru D. L., Wu F.. Global geographical overlap of aflatoxin and hepatitis C: controlling risk factors for liver cancer worldwide. Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment. 2013;30:534–540.

Long Xi-Dai D., Yao Jin-Guang G., Zeng Zhi, et al. Polymorphisms in the coding region of X-ray repair complementing group 4 and aflatoxin B1-related hepatocellular carcinoma. Hepatology (Baltimore, Md.). 2013;58:171–181.

Saad-Hussein Amal, Beshir Safia, Moubarz Gehan, Elserougy Safaa, Ibrahim Mohamed I.. Effect of occupational exposure to aflatoxins on some liver tumor markers in textile workers. American journal of industrial medicine. 2013;56:818–824.

Fares Nadim, Péron Jean-Marie M.. [Epidemiology, natural history, and risk factors of hepatocellular carcinoma]. La Revue du praticien. 2013;63.

Fang Yi, Feng Youjun, Wu Tongjin, et al. Aflatoxin B1 negatively regulates Wnt/β-catenin signaling pathway through activating miR-33a. PloS one. 2013;8.

Felizardo Raphael J., Câmara Niels O.. Hepatocellular carcinoma and food contamination: aflatoxins and ochratoxin A as a great prompter. World journal of gastroenterology : WJG. 2013;19:3723–3725.

Yeganeh Behzad, Hashemi Mohammad, Serres Fredrick J., Los Marek J., Ghavami Saeid. Different faces of hepatocellular carcinoma as a health threat in 21st century. Hepatitis monthly. 2013;13.

Niu Yongdong, Wu Zheng, Shen Qiujin, et al. Hepatitis B virus X protein co-activates pregnane X receptor to induce the cytochrome P450 3A4 enzyme, a potential implication in hepatocarcinogenesis. Digestive and liver disease. 2013;45:1041–1048.

Chen Jian-Guo G., Egner Patricia A., Ng Derek, et al. Reduced aflatoxin exposure presages decline in liver cancer mortality in an endemic region of China. Cancer prevention research (Philadelphia, Pa.). 2013;6:1038–1045.

Kew Michael C.. Aflatoxins as a cause of hepatocellular carcinoma. Journal of gastrointestinal and liver diseases : JGLD. 2013;22:305–310.

Moudgil Vandana, Redhu Davender, Dhanda Suman, Singh Jasbir. A review of molecular mechanisms in the development of hepatocellular carcinoma by aflatoxin and hepatitis B and C viruses. Journal of environmental pathology, toxicology and oncology. 2013;32:165–175.

Zhang Yu-Jing J., Wu Hui-Chen C., Yazici Hulya, Yu Ming-Whei W., Lee Po-Huang H., Santella Regina M.. Global hypomethylation in hepatocellular carcinoma and its relationship to aflatoxin B(1) exposure. World journal of hepatology. 2012;4:169–175.

Feng Ying, Xue Wan-Jiang J., Li Peng, et al. RASSF1A hypermethylation is associated with aflatoxin B1 and polycyclic aromatic hydrocarbon exposure in hepatocellular carcinoma. Hepato-gastroenterology. 2012;59:1883–1888.

Kew Michael C.. Hepatocellular carcinoma in developing countries: Prevention, diagnosis and treatment. World journal of hepatology. 2012;4:99–104.

Liu Yan, Chang Chung-Chou C., Marsh Gary M., Wu Felicia. Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. European journal of cancer (Oxford, England : 1990). 2012;48:2125–2136.

Doktorova Tatyana Y., Ellinger-Ziegelbauer Heidrun, Vinken Mathieu, et al. Comparison of hepatocarcinogen-induced gene expression profiles in conventional primary rat hepatocytes with in vivo rat liver. Archives of toxicology. 2012;86:1399–1411.

Ma Yanli, Kong Qingbin, Hua Hui, Luo Ting, Jiang Yangfu. Aflatoxin B1 up-regulates insulin receptor substrate 2 and stimulates hepatoma cell migration. PloS one. 2012;7.

Lereau Myriam, Gouas Doriane, Villar Stéphanie, et al. Interactions between hepatitis B virus and aflatoxin B(1): effects on p53 induction in HepaRG cells. The Journal of general virology. 2012;93:640–650.

Wu Hui Chen C., Santella Regina. The role of aflatoxins in hepatocellular carcinoma. Hepatitis monthly. 2012;12.

Villar Stephanie, Ortiz-Cuaran Sandra, Abedi-Ardekani Behnoush, et al. Aflatoxin-induced TP53 R249S mutation in hepatocellular carcinoma in Thailand: association with tumors developing in the absence of liver cirrhosis. PloS one. 2012;7.

Gao Jing, Xie Li, Yang Wan-Shui S., et al. Risk factors of hepatocellular carcinoma–current status and perspectives. Asian Pacific journal of cancer prevention : APJCP. 2012;13:743–752.

Jeannot Emmanuelle, Boorman Gary A., Kosyk Oksana, et al. Increased incidence of aflatoxin B1-induced liver tumors in hepatitis virus C transgenic mice. International journal of cancer. Journal international du cancer. 2012;130:1347–1356.

Wogan Gerald N., Kensler Thomas W., Groopman John D.. Present and future directions of translational research on aflatoxin and hepatocellular carcinoma. A review. Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment. 2012;29:249–257.

Williams David E.. The rainbow trout liver cancer model: response to environmental chemicals and studies on promotion and chemoprevention. Comparative biochemistry and physiology. Toxicology & pharmacology : CBP. 2012;155:121–127.

Woo Leslie L., Egner Patricia A., Belanger Crystal L., et al. Aflatoxin B1-DNA adduct formation and mutagenicity in livers of neonatal male and female B6C3F1 mice. Toxicological sciences : an official journal of the Society of Toxicology. 2011;122:38–44.

Long Xi-Dai D., Yao Jin-Guang G., Huang Yong-Zhi Z., et al. DNA repair gene XRCC7 polymorphisms (rs#7003908 and rs#10109984) and hepatocellular carcinoma related to AFB1 exposure among Guangxi population, China. Hepatology research : the official journal of the Japan Society of Hepatology. 2011;41:1085–1093.

Asim Mohammad, Sarma Manash P., Thayumanavan L., Kar P.. Role of aflatoxin B1 as a risk for primary liver cancer in north Indian population. Clinical biochemistry. 2011;44:1235–1240.

Gursoy-Yuzugullu Ozge, Yuzugullu Haluk, Yilmaz Mustafa, Ozturk Mehmet. Aflatoxin genotoxicity is associated with a defective DNA damage response bypassing p53 activation. Liver international. 2011;31:561–571.

Shirabe Ken, Toshima Takeo, Taketomi Akinobu, et al. Hepatic aflatoxin B1-DNA adducts and TP53 mutations in patients with hepatocellular carcinoma despite low exposure to aflatoxin B1 in southern Japan. Liver international. 2011;31:1366–1372.

Li Chang-Hai H., Wang Yan-Jun J., Dong Wei, et al. Hepatic oval cell lines generate hepatocellular carcinoma following transfection with HBx gene and treatment with aflatoxin B1 in vivo. Cancer letters. 2011;311:1–10.

McGlynn Katherine A., London W. Thomas. The global epidemiology of hepatocellular carcinoma: present and future. Clinics in liver disease. 2011;15:223–243.

Umoh Nsikak J., Lesi Olufunmilayo A., Mendy Maimuna, et al. Aetiological differences in demographical, clinical and pathological characteristics of hepatocellular carcinoma in The Gambia. Liver international. 2011;31:215–221.

Liu Shih-Ping P., Li Ying-Shiuan S., Lee Cheng-Ming M., et al. Higher susceptibility to aflatoxin B(1)-related hepatocellular carcinoma in glycine N-methyltransferase knockout mice. International journal of cancer. Journal international du cancer. 2011;128:511–523.

Vivekanandan Perumal, Torbenson Michael, Ramakrishna Banumathi. Hepatitis B virus-associated hepatocellular carcinoma from India: role of viral genotype and mutations in CTNNB1 (beta-catenin) and TP53 genes. Journal of gastrointestinal cancer. 2011;42:20–25.

Ozdemir Filiz Türe T., Tiftikci Arzu, Sancak Seda, et al. The prevalence of the mutation in codon 249 of the P53 gene in patients with hepatocellular carcinoma (HCC) in Turkey. Journal of gastrointestinal cancer. 2010;41:185–189.

Zeng Chunxian, Wang Ruizhi, Li Daochuan, et al. A novel GSK-3 beta-C/EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma. Hepatology (Baltimore, Md.). 2010;52:1702–1712.

Benford Diane, Leblanc Jean-Charles C., Setzer R. Woodrow. Application of the margin of exposure (MoE) approach to substances in food that are genotoxic and carcinogenic: example: aflatoxin B1 (AFB1). Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 2010;48 Suppl 1.

Ubagai Tsuneyuki, Kikuchi Takane, Fukusato Toshio, Ono Yasuo. Aflatoxin B1 modulates the insulin-like growth factor-2 dependent signaling axis. Toxicology in vitro : an international journal published in association with BIBRA. 2010;24:783–789.

Liu Yan, Wu Felicia. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environmental health perspectives. 2010;118:818–824.

Xu Li, Qian Guoqing, Tang Lili, Su Jianjia, Wang Jia-Sheng S.. Genetic variations of hepatitis B virus and serum aflatoxin-lysine adduct on high risk of hepatocellular carcinoma in Southern Guangxi, China. Journal of hepatology. 2010;53:671–676.

Nordenstedt Helena, White Donna L., El-Serag Hashem B.. The changing pattern of epidemiology in hepatocellular carcinoma. Digestive and liver disease. 2010;42 Suppl 3:S206–S214.

Wang Shen-Nien N., Lee King-Teh T., Ker Chen-Guo G.. Leptin in hepatocellular carcinoma. World journal of gastroenterology : WJG. 2010;16:5801–5809.

Zhang Yu-Jing J.. Interactions of chemical carcinogens and genetic variation in hepatocellular carcinoma. World journal of hepatology. 2010;2:94–102.

Lu Pei-xin X., Wang Jin-bing B., Zhang Qi-nan N., Wu Yan, Sun Yan, Chen Tao-yang Y.. [Longitudinal study of aflatoxin exposure in the development of primary liver cancer in patients with chronic hepatitis]. Zhonghua yi xue za zhi. 2010;90:1665–1669.

Oyagbemi A. A., Azeez O. I., Saba A. B.. Hepatocellular carcinoma and the underlying mechanisms. African health sciences. 2010;10:93–98.

Luke Colin, Price Timothy, Roder David. Epidemiology of cancer of the liver and intrahepatic bile ducts in an Australian population. Asian Pacific journal of cancer prevention : APJCP. 2010;11:1479–1485.

Sanyal Arun J., Yoon Seung Kew K., Lencioni Riccardo. The etiology of hepatocellular carcinoma and consequences for treatment. The oncologist. 2010;15 Suppl 4:14–22.

Blonski Wojciech, Kotlyar David S., Forde Kimberly A.. Non-viral causes of hepatocellular carcinoma. World journal of gastroenterology : WJG. 2010;16:3603–3615.

Long Xi-Dai D., Ma Yun, Zhou Yuan-Feng F., Ma Ai-Min M., Fu Guo-Hui H.. Polymorphism in xeroderma pigmentosum complementation group C codon 939 and aflatoxin B1-related hepatocellular carcinoma in the Guangxi population. Hepatology (Baltimore, Md.). 2010;52:1301–1309.

Tornai István. [Role of environmental factors in the etiology of hepatocellular carcinoma]. Orvosi hetilap. 2010;151:1132–1136.

Gouas Doriane A., Shi Hong, Hautefeuille Agnès H., et al. Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein. Carcinogenesis. 2010;31:1475–1482.

Kew Michael C.. Prevention of hepatocellular carcinoma. Annals of hepatology. 2010;9:120–132.

Johnson N. M.. Qian G, Xu L., Tietze D., Marroquin-Cardona A., Robinson A., Rodriguez M., Kaufman L., Cunningham K., Wittmer J., Guerra F., Donnelly K.D., Williams J.H., Wang J.S., Phillips T.D. Aflatoxin and PAH exposure biomarkers in a U.S. population with a high incidence of hepatocellular carcinoma. Sci Total Environment. 2010 Nov. 1; 408(23):6027.

Williams Jonathan H., Grubb Jessica A., Davis Jerry W., et al. HIV and hepatocellular and esophageal carcinomas related to consumption of mycotoxin-prone foods in sub-Saharan Africa. The American journal of clinical nutrition. 2010;92:154–160.

Ocama P., Nambooze S., Opio C. K., Shiels M. S., Wabinga H. R., Kirk G. D.. Trends in the incidence of primary liver cancer in Central Uganda, 1960-1980 and 1991-2005. British journal of cancer. 2009;100:799–802.

Fan Jian-Gao G., Farrell Geoffrey C., Asia-Pacific Working Party for Prevention of Hepatocellular Carcinoma . Prevention of hepatocellular carcinoma in nonviral-related liver diseases. Journal of gastroenterology and hepatology. 2009;24:712–719.

Wild Christopher P., Montesano Ruggero. A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention. Cancer letters. 2009;286:22–28.

Reed C. A., Mayhew C. N., McClendon A. K., Yang X., Witkiewicz A., Knudsen E. S.. RB has a critical role in mediating the in vivo checkpoint response, mitigating secondary DNA damage and suppressing liver tumorigenesis initiated by aflatoxin B1. Oncogene. 2009;28:4434–4443.

Schütte Kerstin, Bornschein Jan, Malfertheiner Peter. Hepatocellular carcinoma–epidemiological trends and risk factors. Digestive diseases (Basel, Switzerland). 2009;27:80–92.

Vineis P., Xun W.. The emerging epidemic of environmental cancers in developing countries. Annals of oncology. 2009;20:205–212.

Besaratinia Ahmad, Kim Sang-In I., Hainaut Pierre, Pfeifer Gerd P.. In vitro recapitulating of TP53 mutagenesis in hepatocellular carcinoma associated with dietary aflatoxin B1 exposure. Gastroenterology. 2009;137.

Wu Hui-Chen C., Wang Qiao, Yang Hwai-I I., et al. Aflatoxin B1 exposure, hepatitis B virus infection, and hepatocellular carcinoma in Taiwan. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2009;18:846–853.

Long Xi Dai D., Ma Yun, Zhou Yun Feng F., et al. XPD codon 312 and 751 polymorphisms, and AFB1 exposure, and hepatocellular carcinoma risk. BMC cancer. 2009;9.

Ji Long, Yu Hongping. [Relationship of single nucleotide polymorphism, environmental factors and the hereditary susceptibility of hepatocellular carcinoma]. Wei sheng yan jiu = Journal of hygiene research. 2009;38:233–237.

Cullen John M., Brown Danielle L., Kissling Grace E., et al. Aflatoxin B1 and/or hepatitis B virus induced tumor spectrum in a genetically engineered hepatitis B virus expression and Trp53 haploinsufficient mouse model system for hepatocarcinogenesis. Toxicologic pathology. 2009;37:333–342.

Moore Malcolm A.. Diverse influences of dietary factors on cancer in Asia. Asian Pacific journal of cancer prevention : APJCP. 2009;10:981–986.

Chuang Shu-Chun C., La Vecchia Carlo, Boffetta Paolo. Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer letters. 2009;286:9–14.

Wang Jun, Liu Xiu-Mei M., Zhang Zhi-Qiang Q.. [Exposure assessment of liver cancer attributed to dietary aflatoxins exposure in Chinese residents]. Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]. 2009;43:478–481.

Li Yuan, Wan Dafang, Wei Wei, et al. Candidate genes responsible for human hepatocellular carcinoma identified from differentially expressed genes in hepatocarcinogenesis of the tree shrew (Tupaia belangeri chinesis). Hepatology research : the official journal of the Japan Society of Hepatology. 2008;38:85–95.

Hainaut Pierre, Boyle Peter. Curbing the liver cancer epidemic in Africa. Lancet. 2008;371:367–368.

Ferrís I Tortajada J., Ortega García J. A., Garcia I Castell J., López Andreu J. A., Ribes Koninckx C., Berbel Tornero O.. [Risks factors for pediatric malignant liver tumors]. Anales de pediatría (Barcelona, Spain : 2003). 2008;68:377–384.

Paget Vincent, Sichel François, Garon David, Lechevrel Mathilde. Aflatoxin B1-induced TP53 mutational pattern in normal human cells using the FASAY (Functional Analysis of Separated Alleles in Yeast). Mutation research. 2008;656:55–61.

Raoul Jean-Luc L.. Natural history of hepatocellular carcinoma and current treatment options. Seminars in nuclear medicine. 2008;38.

Wu Hui-Chen C., Wang Qiao, Yang Hwai-I I., et al. Urinary 15-F2t-isoprostane, aflatoxin B1 exposure and hepatitis B virus infection and hepatocellular carcinoma in Taiwan. Carcinogenesis. 2008;29:971–976.

Li Yuan, Qin Xue, Cui Jiefeng, et al. Proteome analysis of aflatoxin B1-induced hepatocarcinogenesis in tree shrew (Tupaia belangeri chinensis) and functional identification of candidate protein peroxiredoxin II. Proteomics. 2008;8:1490–1501.

Anwar Wagida A., Khaled Hussein M., Amra Hassan A., El-Nezami Hani, Loffredo Christopher A.. Changing pattern of hepatocellular carcinoma (HCC) and its risk factors in Egypt: possibilities for prevention. Mutation research. 2008;659:176–184.

Groopman John D., Kensler Thomas W., Wild Christopher P.. Protective interventions to prevent aflatoxin-induced carcinogenesis in developing countries. Annual review of public health. 2008;29:187–203.

Pineau Pascal, Marchio Agnès, Battiston Carlo, et al. Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure. Mutation research. 2008;653:6–13.

Long Xi Dai D., Ma Yun, Qu De Ying e. . Y., et al. The polymorphism of XRCC3 codon 241 and AFB1-related hepatocellular carcinoma in Guangxi population, China. Annals of epidemiology. 2008;18:572–578.

Park Sohee, Bae Jisuk, Nam Byung-Ho H., Yoo Keun-Young Y.. Aetiology of cancer in Asia. Asian Pacific journal of cancer prevention : APJCP. 2008;9:371–380.

Long Xi-dai D., Ma Yun, Deng Zhuo-lin L., Huang Yong-zhi Z., Wei Ni-bo B.. [Association of the Thr241Met polymorphism of DNA repair gene XRCC3 with genetic susceptibility to AFB1-related hepatocellular carcinoma in Guangxi population]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics. 2008;25:268–271.

Murugavel Kailapuri G., Mathews S., Jayanthi V., et al. Alpha-fetoprotein as a tumor marker in hepatocellular carcinoma: investigations in south Indian subjects with hepatotropic virus and aflatoxin etiologies. International journal of infectious diseases : IJID. 2008;12.

Gomaa Asmaa-Ibrahim I., Khan Shahid-A A., Toledano Mireille-B B., Waked Imam, Taylor-Robinson Simon-D D.. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World journal of gastroenterology : WJG. 2008;14:4300–4308.

Pang Yaqin, Li Wenxue, Ma Rulin, et al. Development of human cell models for assessing the carcinogenic potential of chemicals. Toxicology and applied pharmacology. 2008;232:478–486.

Kuniholm Mark H., Lesi Olufunmilayo A., Mendy Maimuna, et al. Aflatoxin exposure and viral hepatitis in the etiology of liver cirrhosis in the Gambia, West Africa. Environmental health perspectives. 2008;116:1553–1557.

Abdel-Wahab M., Mostafa M., Sabry M., Farrash M., Yousef Tamer. Aflatoxins as a risk factor for hepatocellular carcinoma in Egypt, Mansoura Gastroenterology Center study. Hepato-gastroenterology. 2008;55:1754–1759.

Peng Tao, Li Le-Qun Q., Peng Min-Hao H., et al. Is correction for protein concentration appropriate for protein adduct dosimetry? Hypothesis and clues from an aflatoxin B1-exposed population. Cancer science. 2007;98:140–146.

Murugavel K. G., Naranatt P. P., Shankar E. M., et al. Prevalence of aflatoxin B1 in liver biopsies of proven hepatocellular carcinoma in India determined by an in-house immunoperoxidase test. Journal of medical microbiology. 2007;56:1455–1459.

Jiao Yang, Ban Ke-chen C., Cao Ji, Yue Hai-ying Y., Chen Mao-wei W., Su Jian-jia J.. [Changes of beta catenin in carcinogenesis in rat livers induced by aflatoxin B1]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology. 2007;15:783–784.

Wu Hui-Chen C., Wang Qiao, Wang Lian-Wen W., et al. Urinary 8-oxodeoxyguanosine, aflatoxin B1 exposure and hepatitis B virus infection and hepatocellular carcinoma in Taiwan. Carcinogenesis. 2007;28:995–999.

Hussain S. P., Schwank J., Staib F., Wang X. W., Harris C. C.. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene. 2007;26:2166–2176.

Mokhles M., Abd El Wahhab M. A., Tawfik M., Ezzat W., Gamil K., Ibrahim M.. Detection of aflatoxin among hepatocellular carcinoma patients in Egypt. Pakistan journal of biological sciences: PJBS. 2007;10:1422–1429.

Lu Hai-xia X., Feng Zhen-bo B., Feng Xiao-lan L.. [A case-control study on the association of hepatocellular carcinoma with genetic polymorphisms of CYP3A5 in a highly aflatoxin B1 contaminated Guangxi area]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology. 2007;15:705–706.

Guillouzo André, Corlu Anne, Aninat Caroline, Glaise Denise, Morel Fabrice, Guguen-Guillouzo Christiane. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chemico-biological interactions. 2007;168:66–73.

Wu Hui-Chen C., Wang Qiao, Wang Lian-Wen W., et al. Polycyclic aromatic hydrocarbon- and aflatoxin-albumin adducts, hepatitis B virus infection and hepatocellular carcinoma in Taiwan. Cancer letters. 2007;252:104–114.

Habib Samy L., Said Boctor, Awad Ahmed T., Mostafa Mostafa H., Shank Ronald C.. Novel adenine adducts, N7-guanine-AFB1 adducts, and p53 mutations in patients with schistosomiasis and aflatoxin exposure. Cancer detection and prevention. 2006;30:491–498.

Chen Xiaoping, Wang Haijian, Xie Weimin, et al. Association of CYP1A2 genetic polymorphisms with hepatocellular carcinoma susceptibility: a case-control study in a high-risk region of China. Pharmacogenetics and genomics. 2006;16:219–227.

Ananthakrishnan Ashwin, Gogineni Veena, Saeian Kia. Epidemiology of primary and secondary liver cancers. Seminars in interventional radiology. 2006;23:47–63.

Motola-Kuba Daniel, Zamora-Valdés Daniel, Uribe Misael, Méndez-Sánchez Nahum. Hepatocellular carcinoma. An overview. Annals of hepatology. 2006;5:16–24.

Tong Wei-Min M., Lee Ming-Kei K., Galendo Dominique, Wang Zhao-Qi Q., Sabapathy Kanaga. Aflatoxin-B exposure does not lead to p53 mutations but results in enhanced liver cancer of Hupki (human p53 knock-in) mice. International journal of cancer. Journal international du cancer. 2006;119:745–749.

Zhang Yu-Jing J., Rossner Pavel, Chen Yu, et al. Aflatoxin B1 and polycyclic aromatic hydrocarbon adducts, p53 mutations and p16 methylation in liver tissue and plasma of hepatocellular carcinoma patients. International journal of cancer. Journal international du cancer. 2006;119:985–991.

El-Shanawani Faten M., Abdel-Hadi Afaf A., Abu Zikri Nadia B., Ismail Alaa, El-Ansary Mahmoud, El-Raai Ahmed. Clinical significance of aflatoxin, mutant P53 gene and sIL-2 receptor in liver cirrhosis and hepatocellular carcinoma. Journal of the Egyptian Society of Parasitology. 2006;36:221–239.

Kamdem Landry K., Meineke Ingolf, Gödtel-Armbrust Ute, Brockmöller Jürgen, Wojnowski Leszek. Dominant contribution of P450 3A4 to the hepatic carcinogenic activation of aflatoxin B1. Chemical research in toxicology. 2006;19:577–586.

McKillop Iain H., Moran Diarmuid M., Jin Xiaoling, Koniaris Leonidas G.. Molecular pathogenesis of hepatocellular carcinoma. The Journal of surgical research. 2006;136:125–135.

Lodato Francesca, Mazzella Giuseppe, Festi Davide, Azzaroli Francesco, Colecchia Antonio, Roda Enrico. Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World journal of gastroenterology : WJG. 2006;12:7239–7249.

Farazi Paraskevi A., DePinho Ronald A.. The genetic and environmental basis of hepatocellular carcinoma. Discovery medicine. 2006;6:182–186.

Long Xi Dai D., Ma Yun, Wei Yi Ping P., Deng Zhou Lin L.. The polymorphisms of GSTM1, GSTT1, HYL1*2, and XRCC1, and aflatoxin B1-related hepatocellular carcinoma in Guangxi population, China. Hepatology research : the official journal of the Japan Society of Hepatology. 2006;36:48–55.

Kirk Gregory D., Bah Ebrima, Montesano Ruggero. Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa. Carcinogenesis. 2006;27:2070–2082.

Chang Chin-Kuo K., Astrakianakis George, Thomas David B., et al. Occupational exposures and risks of liver cancer among Shanghai female textile workers–a case-cohort study. International journal of epidemiology. 2006;35:361–369.

Lian Min, Liu Ying, Yu Shun-Zhang Z., Qian Geng-Sun S., Wan Shu-Guang G., Dixon Kenneth-R R.. Hepatitis B virus x gene and cyanobacterial toxins promote aflatoxin B1-induced hepatotumorigenesis in mice. World journal of gastroenterology : WJG. 2006;12:3065–3072.

Seitz Helmut K., Stickel Felix. Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biological chemistry. 2006;387:349–360.

Gao Ji-Dong D., Shao Yong-Fu F., Xu Yang, et al. Tight association of hepatocellular carcinoma with HBV infection in North China. Hepatobiliary & pancreatic diseases international : HBPD INT. 2005;4:46–49.

Kuang Shuang-Yuan Y., Lekawanvijit Suree, Maneekarn Niwat, et al. Hepatitis B 1762T/1764A mutations, hepatitis C infection, and codon 249 p53 mutations in hepatocellular carcinomas from Thailand. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2005;14:380–384.

McGlynn Katherine A., London W. Thomas. Epidemiology and natural history of hepatocellular carcinoma. Best practice & research. Clinical gastroenterology. 2005;19:3–23.

Cha Charles, Dematteo Ronald P.. Molecular mechanisms in hepatocellular carcinoma development. Best practice & research. Clinical gastroenterology. 2005;19:25–37.

El-Kafrawy Sherif A., Abdel-Hamid Mohamed, El-Daly Mai, et al. P53 mutations in hepatocellular carcinoma patients in Egypt. International journal of hygiene and environmental health. 2005;208:263–270.

Duan Xiao-Xian X., Ou Jing-Sheng S., Li Yuan, et al. Dynamic expression of apoptosis-related genes during development of laboratory hepatocellular carcinoma and its relation to apoptosis. World journal of gastroenterology : WJG. 2005;11:4740–4744.

Arsura Marcello, Cavin Lakita G.. Nuclear factor-kappaB and liver carcinogenesis. Cancer letters. 2005;229:157–169.

Kirk Gregory D., Lesi Olufunmilayo A., Mendy Maimuna, et al. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene. 2005;24:5858–5867.

Zhang Yu-jing J., Chen Yu, Ahsan Habibul, et al. Silencing of glutathione S-transferase P1 by promoter hypermethylation and its relationship to environmental chemical carcinogens in hepatocellular carcinoma. Cancer letters. 2005;221:135–143.

Groopman John D., Kensler Thomas W.. Role of metabolism and viruses in aflatoxin-induced liver cancer. Toxicology and applied pharmacology. 2005;206:131–137.

Kirk Gregory D., Turner Paul C., Gong Yunyun, et al. Hepatocellular carcinoma and polymorphisms in carcinogen-metabolizing and DNA repair enzymes in a population with aflatoxin exposure and hepatitis B virus endemicity. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2005;14:373–379.

Bedard Leanne L., Alessi Manlio, Davey Scott, Massey Thomas E.. Susceptibility to aflatoxin B1-induced carcinogenesis correlates with tissue-specific differences in DNA repair activity in mouse and in rat. Cancer research. 2005;65:1265–1270.

Luo Rui-Hong H., Zhao Zhi-Xin X., Zhou Xu-Yu Y., Gao Zhi-Liang L., Yao Ji-Lu L.. Risk factors for primary liver carcinoma in Chinese population. World journal of gastroenterology : WJG. 2005;11:4431–4434.

Long Xi-dai D., Ma Yun, Wei Yi-ping P., Deng Zhuo-lin L.. [A study about the association of detoxication gene GSTM1 polymorphism and the susceptibility to aflatoxin B1-related hepatocellular carcinoma]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology. 2005;13:668–670.

Kensler Thomas W., Egner Patricia A., Wang Jin-Bing B., et al. Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterology. 2004;127.

Cupid B. C., Lightfoot T. J., Russell D., et al. The formation of AFB(1)-macromolecular adducts in rats and humans at dietary levels of exposure. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 2004;42:559–569.

Aflatoxins. Report on carcinogens : carcinogen profiles / U.S. Dept. of Health and Human Services, Public Health Service, National Toxicology Program. 2004;11.

Li Yuan, Wan Da-Fang F., Su Jian-Jia J., et al. Differential expression of genes during aflatoxin B(1)-induced hepatocarcinogenesis in tree shrews. World journal of gastroenterology : WJG. 2004;10:497–504.

Chen Ban Ke, Singh Harjit, Krishnan R., Fong Seow Heng. Comparison of the expression of beta-catenin in hepatocellular carcinoma in areas with high and low levels of exposure to aflatoxin B1. Journal of surgical oncology. 2004;86:157–163.

Gelderblom W. C., Rheeder J. P., Leggott N., et al. Fumonisin contamination of a corn sample associated with the induction of hepatocarcinogenesis in rats-role of dietary deficiencies. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 2004;42:471–479.

Roebuck B. D.. Hyperplasia, partial hepatectomy, and the carcinogenicity of aflatoxin B1. Journal of cellular biochemistry. 2004;91:243–249.

Sporny StanisŃaw, MusiaŃ Jacek. [Pathogenesis and morphology of hepatocellular carcinoma]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego. 2004;16:293–297.

Majer Bernhard J., Mersch-Sundermann Volker, Darroudi Firouz, Laky Brenda, Wit Kristal, Knasmüller Siegfried. Genotoxic effects of dietary and lifestyle related carcinogens in human derived hepatoma (HepG2, Hep3B) cells. Mutation research. 2004;551:153–166.

Srivatanakul Petcharin, Sriplung Hutcha, Deerasamee Somyos. Epidemiology of liver cancer: an overview. Asian Pacific journal of cancer prevention : APJCP. 2004;5:118–125.

Marotta F., Vangieri B., Cecere A., Gattoni A.. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect. La Clinica terapeutica. 2004;155:187–199.

Nizami H. M., Zuberi Sarwar J.. Aflatoxin and liver cancer in Karachi–a preliminary survey. 1977. JPMA. The Journal of the Pakistan Medical Association. 2004;54.

Kuang Shuang-Yuan Y., Jackson Peta E., Wang Jin-Bing B., et al. Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proceedings of the National Academy of Sciences of the United States of America. 2004;101:3575–3580.

Suriawinata Arief, Xu Ruliang. An update on the molecular genetics of hepatocellular carcinoma. Seminars in liver disease. 2004;24:77–88.

Szymańska Katarzyna, Lesi Olufunmilayo A., Kirk Gregory D., et al. Ser-249TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa. International journal of cancer. Journal international du cancer. 2004;110:374–379.

Harris Angela J., Dial Stacey L., Casciano Daniel A.. Comparison of basal gene expression profiles and effects of hepatocarcinogens on gene expression in cultured primary human hepatocytes and HepG2 cells. Mutation research. 2004;549:79–99.

Yu Mimi C., Yuan Jian-Min M.. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology. 2004;127.

Omer Ragaa E., Kuijsten Anneleen, Kadaru Abdelgadir M., et al. Population-attributable risk of dietary aflatoxins and hepatitis B virus infection with respect to hepatocellular carcinoma. Nutrition and cancer. 2004;48:15–21.

Hifnawy M. S., Mangoud Amal M., Eissa Mostafa H., et al. The role of aflatoxin-contaminated food materials and HCV in developing hepatocellular carcinoma in Al-Sharkia Governorate, Egypt. Journal of the Egyptian Society of Parasitology. 2004;34:479–488.

Shupe Thomas, Sell Stewart. Low hepatic glutathione S-transferase and increased hepatic DNA adduction contribute to increased tumorigenicity of aflatoxin B1 in newborn and partially hepatectomized mice. Toxicology letters. 2004;148:1–9.

Su Jian-Jia J., Ban Ke-Chen C., Li Yuan, et al. Alteration of p53 and p21 during hepatocarcinogenesis in tree shrews. World journal of gastroenterology : WJG. 2004;10:3559–3563.
Ellinger-Ziegelbauer Heidrun, Stuart Barry, Wahle Brad, Bomann Werner, Ahr Hans-Jurgen J.. Characteristic expression profiles induced by genotoxic carcinogens in rat liver. Toxicological sciences : an official journal of the Society of Toxicology. 2004;77:19–34.

Li Yuan, Su Jian Jia J., Cao J. I., et al. [Different gene expression during hepatocarcinogenesis in tree shrew induced by aflatoxin B1]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology. 2003;11:96–98.

Zhang Yu-Jing J., Chen Yu, Ahsan Habibul, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relationship to aflatoxin B1-DNA adducts and p53 mutation in hepatocellular carcinoma. International journal of cancer. Journal international du cancer. 2003;103:440–444.

Dong-Dong Lu, Xi-Ran Zhang. Plasma 249Ser p53 mutation in patients with hepatocellular carcinoma residing in a high risk area. Journal of cellular and molecular medicine. 2003;7:89–92.

Cengiz Cem, Akarca Ulus S., Goker Erdem, Yuce Gul. Detection of mutant p53 in hepatocellular cancer from Turkey and its correlation with clinicopathologic parameters. Digestive diseases and sciences. 2003;48:865–869.

Sotomayor Rene E., Washington Melissa, Nguyen Linh, Nyang’anyi Rahma, Hinton Dennis M., Chou Ming. Effects of intermittent exposure to aflatoxin B1 on DNA and RNA adduct formation in rat liver: dose-response and temporal patterns. Toxicological sciences : an official journal of the Society of Toxicology. 2003;73:329–338.

Kensler Thomas W., Qian Geng-Sun S., Chen Jian-Guo G., Groopman John D.. Translational strategies for cancer prevention in liver. Nature reviews. Cancer. 2003;3:321–329.

Nayak N. C.. Hepatocellular carcinoma–a model of human cancer: clinico-pathological features, etiology and pathogenesis. Indian journal of pathology & microbiology. 2003;46:1–16.

Praml Christian, Savelyeva Larissa, Schwab Manfred. Aflatoxin B1 aldehyde reductase (AFAR) genes cluster at 1p35-1p36.1 in a region frequently altered in human tumour cells. Oncogene. 2003;22:4765–4773.

Jackson Peta E., Kuang Shuang-Yuan Y., Wang Jin-Bing B., et al. Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients. Carcinogenesis. 2003;24:1657–1663.

Li Yuan, Su Jian-Jia J., Cao Ji, et al. [Differentially expressed genes in hepatocellular carcinoma of tree shrew induced by different factors]. Ai zheng = Aizheng = Chinese journal of cancer. 2003;22:1018–1022.

Lu Frank C.. Assessment of safety/risk vs. Public health concerns: Aflatoxins and hepatocarcinoma. Environmental health and preventive medicine. 2003;7:235–238.

Novak Kris. Cancer susceptibility: role of genes, environment, and diet. MedGenMed : Medscape general medicine. 2003;5.

McGlynn Katherine A., Hunter Kent, LeVoyer Thomas, et al. Susceptibility to aflatoxin B1-related primary hepatocellular carcinoma in mice and humans. Cancer research. 2003;63:4594–4601.

Solís-Herruzo J. A.. Hepatocellular carcinoma. Epidemiology and etiological factors. Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva. 2003;95.

Edamoto Yoshihiro, Hara Akira, Biernat Wojciech, et al. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. International journal of cancer. Journal international du cancer. 2003;106:334–341.

Yang Chuanwei, Sun Mingzeng, Ilic Zoran, Friedrich Thomas D., Sell Stewart. Reduced expression of p27kip1 and increased hepatocyte proliferation in p53-deficient mice. Molecular carcinogenesis. 2003;36:15–22.

Sell Stewart. Mouse models to study the interaction of risk factors for human liver cancer. Cancer research. 2003;63:7553–7562.

Su Jian-Jia J., Li Yuan, Ban Ke-Chen C., et al. Alteration of the p53 gene during tree shrews’ hepatocarcinogenesis. Hepatobiliary & pancreatic diseases international : HBPD INT. 2003;2:612–616.

Kew Michael C.. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver international. 2003;23:405–409.

Angsubhakorn Subhkij, Pradermwong Apichat, Phanwichien Kanthimani, Nguansangiam Sudarat. Promotion of aflatoxin B1-induced hepatocarcinogenesis by dichlorodiphenyl trichloroethane (DDT). The Southeast Asian journal of tropical medicine and public health. 2002;33:613–623.

Turner Paul C., Sylla Abdoulaye, Diallo Mamadou S., Castegnaro Jean-Jacques J., Hall Andrew J., Wild Christopher P.. The role of aflatoxins and hepatitis viruses in the etiopathogenesis of hepatocellular carcinoma: A basis for primary prevention in Guinea-Conakry, West Africa. Journal of gastroenterology and hepatology. 2002;17 Suppl.

Yu Shun-Zhang Z., Huang Xin-En E., Koide Tsuneo, et al. Hepatitis B and C viruses infection, lifestyle and genetic polymorphisms as risk factors for hepatocellular carcinoma in Haimen, China. Japanese journal of cancer research : Gann. 2002;93:1287–1292.

Ming Lihua, Thorgeirsson Snorri S., Gail Mitchell H., et al. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology (Baltimore, Md.). 2002;36:1214–1220.

El-Serag Hashem B.. Hepatocellular carcinoma: an epidemiologic view. Journal of clinical gastroenterology. 2002;35.

Guyton Kathryn Z., Kensler Thomas W.. Prevention of liver cancer. Current oncology reports. 2002;4:464–470.

Zhang Yu-Jing J., Ahsan Habibul, Chen Yu, et al. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma. Molecular carcinogenesis. 2002;35:85–92.

Montalto Giuseppe, Cervello Melchiorre, Giannitrapani Lydia, Dantona Fabio, Terranova Angela, Castagnetta Luigi A.. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Annals of the New York Academy of Sciences. 2002;963:13–20.

Smela Maryann E., Hamm Michelle L., Henderson Paul T., Harris Constance M., Harris Thomas M., Essigmann John M.. The aflatoxin B(1) formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 2002;99:6655–6660.

Shen Lanlan, Ahuja Nita, Shen Yu, et al. DNA methylation and environmental exposures in human hepatocellular carcinoma. Journal of the National Cancer Institute. 2002;94:755–761.

Henry Sara H., Bosch F. Xavier, Bowers J. C.. Aflatoxin, hepatitis and worldwide liver cancer risks. Advances in experimental medicine and biology. 2002;504:229–233.

Gelderblom W. C., Marasas W. F., Lebepe-Mazur S., Swanevelder S., Vessey C. J., Hall P. de la e. . L.. Interaction of fumonisin B(1) and aflatoxin B(1) in a short-term carcinogenesis model in rat liver. Toxicology. 2002;171:161–173.

Yakicier M. C., Legoix P., Vaury C., et al. Identification of homozygous deletions at chromosome 16q23 in aflatoxin B1 exposed hepatocellular carcinoma. Oncogene. 2001;20:5232–5238.

Stettler P. M., Sengstag C.. Liver carcinogen aflatoxin B1 as an inducer of mitotic recombination in a human cell line. Molecular carcinogenesis. 2001;31:125–138.

Sun C. A., Wang L. Y., Chen C. J., et al. Genetic polymorphisms of glutathione S-transferases M1 and T1 associated with susceptibility to aflatoxin-related hepatocarcinogenesis among chronic hepatitis B carriers: a nested case-control study in Taiwan. Carcinogenesis. 2001;22:1289–1294.

Hiruma S., Gopalan-Kriczky P., Qin G., Gaughan J. P., Lotlikar P. D.. Differential effects of acetaminophen pretreatment on hepatic aflatoxin B(1)-DNA binding, cellular proliferation, and aflatoxin B1-induced hepatic foci in rats and hamsters. Cancer letters. 2001;170:117–124.

Tiemersma E. W., Omer R. E., Bunschoten A., et al. Role of genetic polymorphism of glutathione-S-transferase T1 and microsomal epoxide hydrolase in aflatoxin-associated hepatocellular carcinoma. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2001;10:785–791.

Ahsan H., Wang L. Y., Chen C. J., Tsai W. Y., Santella R. M.. Variability in aflatoxin-albumin adduct levels and effects of hepatitis B and C virus infection and glutathione S-transferase M1 and T1 genotype. Environmental health perspectives. 2001;109:833–837.

Devereux T. R., Stern M. C., Flake G. P., et al. CTNNB1 mutations and beta-catenin protein accumulation in human hepatocellular carcinomas associated with high exposure to aflatoxin B1. Molecular carcinogenesis. 2001;31:68–73.

Stern M. C., Umbach D. M., Yu M. C., London S. J., Zhang Z. Q., Taylor J. A.. Hepatitis B, aflatoxin B(1), and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People’s Republic of China, and a meta-analysis of existing studies. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2001;10:617–625.

Carlson D. B., Williams D. E., Spitsbergen J. M., et al. Fumonisin B1 promotes aflatoxin B1 and N-methyl-N’-nitro-nitrosoguanidine-initiated liver tumors in rainbow trout. Toxicology and applied pharmacology. 2001;172:29–36.

Wang J. S., Huang T., Su J., et al. Hepatocellular carcinoma and aflatoxin exposure in Zhuqing Village, Fusui County, People’s Republic of China. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2001;10:143–146.

Yu S., Zhao N., Zi X.. [The relationship between cyanotoxin (microcystin, MC) in pond-ditch water and primary liver cancer in China]. Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2001;23:96–99.

Chen S. Y., Chen C. J., Chou S. R., et al. Association of aflatoxin B(1)-albumin adduct levels with hepatitis B surface antigen status among adolescents in Taiwan. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2001;10:1223–1226.

Eaton D. L., Bammler T. K., Kelly E. J.. Interindividual differences in response to chemoprotection against aflatoxin-induced hepatocarcinogenesis: implications for human biotransformation enzyme polymorphisms. Advances in experimental medicine and biology. 2001;500:559–576.

Okita K.. [Hepatocarcinogenesis with chemicals including mycotoxins]. Nihon rinsho. Japanese journal of clinical medicine. 2001;59 Suppl 6:76–82.

Lee Y. I., Lee S., Das G. C., Park U. S., Park S. M., Lee Y. I.. Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma. Oncogene. 2000;19:3717–3726.

Wogan G. N.. Impacts of chemicals on liver cancer risk. Seminars in cancer biology. 2000;10:201–210.

Zhang Y. J., Chen S., Tsai W. Y., et al. Expression of cytochrome P450 1A1/2 and 3A4 in liver tissues of hepatocellular carcinoma cases and controls from Taiwan and their relationship to hepatitis B virus and aflatoxin B1-and 4-aminobiphenyl-DNA adducts. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals. 2000;5:295–306.

Chou M. W., Mikhailova M. V., Nichols J., Poirier L. A., Warbritton A., Beland F. A.. Interactive effects of methyl-deficiency and dietary restriction on liver cell proliferation and telomerase activity in Fischer 344 rats pretreated with aflatoxin B(1). Cancer letters. 2000;152:53–61.

Tessitore L., Sesca E., Vance D. E.. Inactivation of phosphatidylethanolamine N-methyltransferase-2 in aflatoxin-induced liver cancer and partial reversion of the neoplastic phenotype by PEMT transfection of hepatoma cells. International journal of cancer. Journal international du cancer. 2000;86:362–367.

Park U. S., Su J. J., Ban K. C., Qin L., Lee E. H., Lee Y. I.. Mutations in the p53 tumor suppressor gene in tree shrew hepatocellular carcinoma associated with hepatitis B virus infection and intake of aflatoxin B1. Gene. 2000;251:73–80.

Banerjee R., Caruccio L., Zhang Y. J., McKercher S., Santella R. M.. Effects of carcinogen-induced transcription factors on the activation of hepatitis B virus expression in human hepatoblastoma HepG2 cells and its implication on hepatocellular carcinomas. Hepatology (Baltimore, Md.). 2000;32:367–374.

Phillips J. C., Davies S., Lake B. G.. Dose-response relationships for hepatic aflatoxin B1-DNA adduct formation in the rat in vivo and in vitro: the use of immunoslot blotting for adduct quantitation. Teratogenesis, carcinogenesis, and mutagenesis. 1999;19:157–170.

Henry S. H., Bosch F. X., Troxell T. C., Bolger P. M.. Policy forum: public health. Reducing liver cancer–global control of aflatoxin. Science (New York, N.Y.). 1999;286:2453–2454.

Wang J., Wang L., Lin S.. [Protection against synergistic hepatocarcinogenesis of hepatitis B virus expression and aflatoxin B1 by antioxidant 2(3)-tert-4 -hydroxyanisole (BHA) in HBV large envelope transgenic mice]. Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]. 1999;33:94–97.

Jackson P. E., Groopman J. D.. Aflatoxin and liver cancer. Baillière’s best practice & research. Clinical gastroenterology. 1999;13:545–555.

Hoque A., Patt Y. Z., Yoffe B., et al. Does aflatoxin B1 play a role in the etiology of hepatocellular carcinoma in the United States? Nutrition and cancer. 1999;35:27–33.

Lin X., Levitsky D. A., King J. M., Campbell T. C.. The promotion effect of anorectic drugs on aflatoxin B(1)-induced hepatic preneoplastic foci. Carcinogenesis. 1999;20:1793–1799.

Sylla A., Diallo M. S., Castegnaro J., Wild C. P.. Interactions between hepatitis B virus infection and exposure to aflatoxins in the development of hepatocellular carcinoma: a molecular epidemiological approach. Mutation research. 1999;428:187–196.

Uwaifo O.. P53 gene of chang-liver cells (Atcc-Ccl13) exposed to aflatoxin B1 (Afb): the effect of lysine on mutation at codon 249 of exon 7. African journal of medicine and medical sciences. 1999;28:71–75.

Chao H. K., Tsai T. F., Lin C. S., Su T. S.. Evidence that mutational activation of the ras genes may not be involved in aflatoxin B(1)-induced human hepatocarcinogenesis, based on sequence analysis of the ras and p53 genes. Molecular carcinogenesis. 1999;26:69–73.

Wogan G. N.. Aflatoxin as a human carcinogen. Hepatology (Baltimore, Md.). 1999;30:573–575.

Sun Z., Lu P., Gail M. H., et al. Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology (Baltimore, Md.). 1999;30:379–383.

Mitacek E. J., Brunnemann K. D., Suttajit M., et al. Exposure to N-nitroso compounds in a population of high liver cancer regions in Thailand: volatile nitrosamine (VNA) levels in Thai food. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 1999;37:297–305.

Li Y., Su J. J., Qin L. L., Yang C., Ban K. C., Yan R. Q.. Synergistic effect of hepatitis B virus and aflatoxin B1 in hepatocarcinogenesis in tree shrews. Annals of the Academy of Medicine, Singapore. 1999;28:67–71.

Su J. J., Qin G. Z., Yan R. Q., Huang D. R., Yang C., Lotlikar P. D.. The expression of insulin-like growth factor II, hepatitis B virus X antigen and p21 in experimental hepatocarcinogenesis in tree shrews. Annals of the Academy of Medicine, Singapore. 1999;28:62–66.

Lu P., Kuang S., Wang J.. [Hepatitis B virus infection and aflatoxin exposure in the development of primary liver cancer]. Zhonghua yi xue za zhi. 1998;78:340–342.

Deng Zhuo-Lin L., Ma Yun. Aflatoxin sufferer and p53 gene mutation in hepatocellular carcinoma. World journal of gastroenterology : WJG. 1998;4:28–29.

Iida N., Sugiyama A., Myoubudani H., et al. Suppression of arachidonic acid cascade-mediated apoptosis in aflatoxin B1-induced rat hepatoma cells by glucocorticoids. Carcinogenesis. 1998;19:1191–1202.

Bailey G. S., Dashwood R., Loveland P. M., Pereira C., Hendricks J. D.. Molecular dosimetry in fish: quantitative target organ DNA adduction and hepatocarcinogenicity for four aflatoxins by two exposure routes in rainbow trout. Mutation research. 1998;399:233–244.

Lee C. C., Liu J. Y., Lin J. K., Chu J. S., Shew J. Y.. p53 point mutation enhanced by hepatic regeneration in aflatoxin B1-induced rat liver tumors and preneoplastic lesions. Cancer letters. 1998;125:1–7.

Ghebranious N., Sell S.. The mouse equivalent of the human p53ser249 mutation p53ser246 enhances aflatoxin hepatocarcinogenesis in hepatitis B surface antigen transgenic and p53 heterozygous null mice. Hepatology (Baltimore, Md.). 1998;27:967–973.

Ghebranious N., Sell S.. Hepatitis B injury, male gender, aflatoxin, and p53 expression each contribute to hepatocarcinogenesis in transgenic mice. Hepatology (Baltimore, Md.). 1998;27:383–391.

Omer R. E., Bakker M. I., Veer P., et al. Aflatoxin and liver cancer in Sudan. Nutrition and cancer. 1998;32:174–180.

Yu S. Z., Chen G., Zhi X. L., Li J.. Primary liver cancer: natural toxins and prevention in China. The Journal of toxicological sciences. 1998;23 Suppl 2:143–147.

Denissenko M. F., Koudriakova T. B., Smith L., O’Connor T. R., Riggs A. D., Pfeifer G. P.. The p53 codon 249 mutational hotspot in hepatocellular carcinoma is not related to selective formation or persistence of aflatoxin B1 adducts. Oncogene. 1998;17:3007–3014.

Root M., Lange T., Campbell T. C.. Dissimilarity in aflatoxin dose-response relationships between DNA adduct formation and development of preneoplastic foci in rat liver. Chemico-biological interactions. 1997;106:213–227.

Chen C. J., Yu M. W., Liaw Y. F.. Epidemiological characteristics and risk factors of hepatocellular carcinoma. Journal of gastroenterology and hepatology. 1997;12.

Ueno Y., Iijima K., Wang S. D., et al. Fumonisins as a possible contributory risk factor for primary liver cancer: a 3-year study of corn harvested in Haimen, China, by HPLC and ELISA. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 1997;35:1143–1150.

Lunn R. M., Zhang Y. J., Wang L. Y., et al. p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer research. 1997;57:3471–3477.

Vidyasagar T., Sujatha N., Sashidhar R. B.. Determination of aflatoxin B1-DNA adduct in rat liver by enzyme immunoassay. The Analyst. 1997;122:609–613.

Yu M. W., Chiang Y. C., Lien J. P., Chen C. J.. Plasma antioxidant vitamins, chronic hepatitis B virus infection and urinary aflatoxin B1-DNA adducts in healthy males. Carcinogenesis. 1997;18:1189–1194.

Oliveira C. A., Germano P. M.. [Aflatoxins: current concepts on mechanisms of toxicity and their involvement in the etiology of hepatocellular carcinoma]. Revista de saúde pública. 1997;31:417–424.

Yu M. W., Lien J. P., Chiu Y. H., Santella R. M., Liaw Y. F., Chen C. J.. Effect of aflatoxin metabolism and DNA adduct formation on hepatocellular carcinoma among chronic hepatitis B carriers in Taiwan. Journal of hepatology. 1997;27:320–330.

Kensler T. W., Gange S. J., Egner P. A., et al. Predictive value of molecular dosimetry: individual versus group effects of oltipraz on aflatoxin-albumin adducts and risk of liver cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 1997;6:603–610.

Macé K., Aguilar F., Wang J. S., et al. Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. Carcinogenesis. 1997;18:1291–1297.

Sengstag C.. The molecular mechanism of aflatoxin B1-induced liver cancer: is mitotic recombination involved? Molecular carcinogenesis. 1997;19:147–152.

Kaplanski C., Chisari F. V., Wild C. P.. Minisatellite rearrangements are increased in liver tumours induced by transplacental aflatoxin B1 treatment of hepatitis B virus transgenic mice, but not in spontaneously arising tumours. Carcinogenesis. 1997;18:633–639.

Ringer D. P., Panzeter P. L., DeCicco L. A.. Alterations in epidermal growth factor binding to hepatic membranes following dietary exposure of rats to known hepatocarcinogens. Toxicology letters. 1997;91:7–12.

Hiruma S., Kimura M., Lehmann K., et al. Potentiation of aflatoxin B1-induced hepatocarcinogenesis in the rat by pretreatment with buthionine sulfoximine. Cancer letters. 1997;113:103–109.

Deng Z., Pan L., Ma Y.. [Sequence alterations in p53 gene of hepatocellular carcinoma from high aflatoxin risk area in Guangxi]. Zhonghua zhong liu za zhi [Chinese journal of oncology]. 1997;19:18–21.

Yu M. W., Lien J. P., Liaw Y. F., Chen C. J.. Effects of multiple risk factors for hepatocellular carcinoma on formation of aflatoxin B1-DNA adducts. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 1996;5:613–619.

Chen C. J., Wang L. Y., Lu S. N., et al. Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology (Baltimore, Md.). 1996;24:38–42.

Chen C. J., Yu M. W., Liaw Y. F., et al. Chronic hepatitis B carriers with null genotypes of glutathione S-transferase M1 and T1 polymorphisms who are exposed to aflatoxin are at increased risk of hepatocellular carcinoma. American journal of human genetics. 1996;59:128–134.

Maxuitenko Y. Y., Curphey T. J., Kensler T. W., Roebuck B. D.. Protection against aflatoxin B1-induced hepatic toxicity as short-term screen of cancer chemopreventive dithiolethiones. Fundamental and applied toxicology. 1996;32:250–259.

Groopman J. D., Scholl P., Wang J. S.. Epidemiology of human aflatoxin exposures and their relationship to liver cancer. Progress in clinical and biological research. 1996;395:211–222.

Yan R. Q., Su J. J., Huang D. R., Gan Y. C., Yang C., Huang G. H.. Human hepatitis B virus and hepatocellular carcinoma. II. Experimental induction of hepatocellular carcinoma in tree shrews exposed to hepatitis B virus and aflatoxin B1. Journal of cancer research and clinical oncology. 1996;122:289–295.

Groopman J. D., Wang J. S., Scholl P.. Molecular biomarkers for aflatoxins: from adducts to gene mutations to human liver cancer. Canadian journal of physiology and pharmacology. 1996;74:203–209.

Guengerich F. P., Johnson W. W., Ueng Y. F., Yamazaki H., Shimada T.. Involvement of cytochrome P450, glutathione S-transferase, and epoxide hydrolase in the metabolism of aflatoxin B1 and relevance to risk of human liver cancer. Environmental health perspectives. 1996;104 Suppl 3:557–562.

Soini Y., Chia S. C., Bennett W. P., et al. An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis. 1996;17:1007–1012.

Wang J. S., Qian G. S., Zarba A., et al. Temporal patterns of aflatoxin-albumin adducts in hepatitis B surface antigen-positive and antigen-negative residents of Daxin, Qidong County, People’s Republic of China. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 1996;5:253–261.

Wild C. P., Hasegawa R., Barraud L., et al. Aflatoxin-albumin adducts: a basis for comparative carcinogenesis between animals and humans. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 1996;5:179–189.

Rivkina M., Cote P. J., Robinson W. S., Tennant B. C., Marion P. L.. Absence of mutations in the p53 tumor suppressor gene in woodchuck hepatocellular carcinomas associated with hepadnavirus infection and intake of aflatoxin B1. Carcinogenesis. 1996;17:2689–2694.

Dycaico M. J., Stuart G. R., Tobal G. M., Boer J. G., Glickman B. W., Provost G. S.. Species-specific differences in hepatic mutant frequency and mutational spectrum among lambda/lacI transgenic rats and mice following exposure to aflatoxin B1. Carcinogenesis. 1996;17:2347–2356.

Orner G. A., Donohoe R. M., Hendricks J. D., Curtis L. R., Williams D. E.. Comparison of the enhancing effects of dehydroepiandrosterone with the structural analog 16 alpha-fluoro-5-androsten-17-one on aflatoxin B1 hepatocarcinogenesis in rainbow trout. Fundamental and applied toxicology. 1996;34:132–140.

Shen H. M., Ong C. N.. Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mutation research. 1996;366:23–44.

Wang L. Y., Hatch M., Chen C. J., et al. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. International journal of cancer. Journal international du cancer. 1996;67:620–625.

Curry G. W., Beattie A. D.. Pathogenesis of primary hepatocellular carcinoma. European journal of gastroenterology & hepatology. 1996;8:850–855.

Johnson P. J.. The epidemiology of hepatocellular carcinoma. European journal of gastroenterology & hepatology. 1996;8:845–849.

Tan C. K., Lo D. S., Law N. M., Ng H. S., Chao T. C.. Blood aflatoxin levels in patients with hepatocellular carcinoma in Singapore. Singapore medical journal. 1995;36:612–614.

Ueda H., Ohkoshi S., Harris C., Jay G.. Synergism between the hbx gene and aflatoxin B-1 in the development of murine liver-cancer. International journal of oncology. 1995;7:735–740.

Liu T. Y., Hwua Y. S., Chao T. W., Chi C. W.. Mechanistic study of the inhibition of aflatoxin b1-induced hepatotoxicity by dimethyl 4,4’-dimethoxy-5,6,5’,6’-dimethylenedioxy biphenyl-2, 2’-dicarboxylate. Cancer letters. 1995;89:201–205.

Orner G. A., Mathews C., Hendricks J. D., Carpenter H. M., Bailey G. S., Williams D. E.. Dehydroepiandrosterone is a complete hepatocarcinogen and potent tumor promoter in the absence of peroxisome proliferation in rainbow trout. Carcinogenesis. 1995;16:2893–2898.

Imazeki F., Yokosuka O., Ohto M., Omata M.. Aflatoxin and p53 abnormality in duck hepatocellular carcinoma. Journal of gastroenterology and hepatology. 1995;10:646–649.

Saracco G.. Primary liver cancer is of multifactorial origin: importance of hepatitis B virus infection and dietary aflatoxin. Journal of gastroenterology and hepatology. 1995;10:604–608.

Izzotti A., Scatolini L., Lewtas J., Walsh D., De Flora S.. Enhanced levels of DNA adducts in the liver of woodchucks infected with hepatitis virus. Chemico-biological interactions. 1995;97:273–285.

Alvarez M. T., Castañeda C., Ruisanchez N., Aleaga M., García E., Escobar M. P.. [Immunological detection of aflatoxin-albumin adducts in children with chronic hepatitis B infection]. G.E.N. 1995;49:36–41.

Carpenter H. M., Zhang Q., Zahr C., Selivonchick D. P., Brock D. E., Curtis L. R.. In vitro and in vivo temperature modulation of hepatic metabolism and DNA adduction of aflatoxin B1 in rainbow trout. Journal of biochemical toxicology. 1995;10:1–10.

Bannasch P., Khoshkhou N. I., Hacker H. J., et al. Synergistic hepatocarcinogenic effect of hepadnaviral infection and dietary aflatoxin B1 in woodchucks. Cancer research. 1995;55:3318–3330.

Liang T. J.. p53 proteins and aflatoxin b1: the good, the bad, and the ugly. Hepatology (Baltimore, Md.). 1995;22:1330–1332.

Duflot A., Mehrotra R., Yu S. Z., Barraud L., Trepo C., Cova L.. Spectrum of liver disease and duck hepatitis B virus infection in a large series of Chinese ducks with hepatocellular carcinoma. Hepatology (Baltimore, Md.). 1995;21:1483–1491.

Ghebranious N., Knoll B. J., Wu H., Lozano G., Sell S.. Characterization of a murine p53ser246 mutant equivalent to the human p53ser249 associated with hepatocellular carcinoma and aflatoxin exposure. Molecular carcinogenesis. 1995;13:104–111.

Curtis L. R., Zhang Q., Zahr C., et al. Temperature-modulated incidence of aflatoxin B1-initiated liver cancer in rainbow trout. Fundamental and applied toxicology. 1995;25:146–153.

McGlynn K. A., Rosvold E. A., Lustbader E. D., et al. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proceedings of the National Academy of Sciences of the United States of America. 1995;92:2384–2387.

Leenadevi T., Valsala K. V., Rajan A.. Aflatoxin induced hepatocarcinogenesis in ducks. Mycotoxin research. 1995;11:2–8.

Webster R. P., Bhattacharya R. K.. Activity of some nuclear enzymes associated with DNA repair following hepatocarcinogen administration to rats. Journal of biochemical toxicology. 1995;10:33–40.

Scholl P., Musser S. M., Kensler T. W., Groopman J. D.. Molecular biomarkers for aflatoxins and their application to human liver cancer. Pharmacogenetics. 1995;5 Spec No.

Campbell T. C.. Correspondence re: G-S. Qian, et al., A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People’s Republic of China. Cancer Epidemiol., Biomarkers & Prev., 3:3-10, 1994, and C.C. Harris, Solving the viral-chemical puzzle of human liver carcinogenesis. Cancer Epidemiol., Biomarkers & Prev., 3:1-2, 1994. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 1994;3:519–521.

Jennings G. S., Heck R., Oesch F., Steinberg P.. Metabolism and cytotoxicity of aflatoxin B1 in cultured rat hepatocytes and nonparenchymal cells: implications for tumorigenesis. Toxicology and applied pharmacology. 1994;129:86–94.

Chao T. C., Lo D. S., Bloodworth B. C., Gunasegaram R., Koh T. H., Ng H. S.. Aflatoxin exposure in Singapore: blood aflatoxin levels in normal subjects, hepatitis B virus carriers and primary hepatocellular carcinoma patients. Medicine, science, and the law. 1994;34:289–298.

Hayes J. D., Nguyen T., Judah D. J., Petersson D. G., Neal G. E.. Cloning of cDNAs from fetal rat liver encoding glutathione S-transferase Yc polypeptides. The Yc2 subunit is expressed in adult rat liver resistant to the hepatocarcinogen aflatoxin B1. The Journal of biological chemistry. 1994;269:20707–20717.

Bailey G. S., Price R. L., Park D. L., Hendricks J. D.. Effect of ammoniation of aflatoxin B1-contaminated cottonseed feedstock on the aflatoxin M1 content of cows’ milk and hepatocarcinogenicity in the trout bioassay. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 1994;32:707–715.

McConnell I. R., Garner R. C.. DNA adducts of aflatoxins, sterigmatocystin and other mycotoxins. IARC scientific publications. 1994:49–55.

Ng I. O., Chung L. P., Tsang S. W., et al. p53 gene mutation spectrum in hepatocellular carcinomas in Hong Kong Chinese. Oncogene. 1994;9:985–990.

Cova L., Mehrotra R., Wild C. P., et al. Duck hepatitis B virus infection, aflatoxin B1 and liver cancer in domestic Chinese ducks. British journal of cancer. 1994;69:104–109.

Harris C. C.. Solving the viral-chemical puzzle of human liver carcinogenesis. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 1994;3:1–2.

Eaton D. L., Gallagher E. P.. Mechanisms of aflatoxin carcinogenesis. Annual review of pharmacology and toxicology. 1994;34:135–172.

Cova L., Duflot A., Prave M., Trepo C.. Duck hepatitis B virus infection, aflatoxin B1 and liver cancer in ducks. Archives of virology. Supplementum. 1993;8:81–87.

Rojanapo W., Kupradinun P., Tepsuwan A., Tanyakaset M.. Effect of varying the onset of exposure to DDT on its modulation of AFB1-induced hepatocarcinogenesis in the rat. Carcinogenesis. 1993;14:663–667.

Soman N. R., Wogan G. N.. Activation of the c-Ki-ras oncogene in aflatoxin B1-induced hepatocellular carcinoma and adenoma in the rat: detection by denaturing gradient gel electrophoresis. Proceedings of the National Academy of Sciences of the United States of America. 1993;90:2045–2049.

Santella R. M., Zhang Y. J., Chen C. J., et al. Immunohistochemical detection of aflatoxin B1-DNA adducts and hepatitis B virus antigens in hepatocellular carcinoma and nontumorous liver tissue. Environmental health perspectives. 1993;99:199–202.

Wild C. P., Jansen L. A., Cova L., Montesano R.. Molecular dosimetry of aflatoxin exposure: contribution to understanding the multifactorial etiopathogenesis of primary hepatocellular carcinoma with particular reference to hepatitis B virus. Environmental health perspectives. 1993;99:115–122.

Hulla J. E., Chen Z. Y., Eaton D. L.. Aflatoxin B1-induced rat hepatic hyperplastic nodules do not exhibit a site-specific mutation within the p53 gene. Cancer research. 1993;53:9–11.

Aguilar F., Hussain S. P., Cerutti P.. Aflatoxin B1 induces the transversion of G–>T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proceedings of the National Academy of Sciences of the United States of America. 1993;90:8586–8590.

Harrison J. C., Carvajal M., Garner R. C.. Does aflatoxin exposure in the United Kingdom constitute a cancer risk? Environmental health perspectives. 1993;99:99–105.

Choy W. N.. A review of the dose-response induction of DNA adducts by aflatoxin B1 and its implications to quantitative cancer-risk assessment. Mutation research. 1993;296:181–198.

Hollstein M. C., Wild C. P., Bleicher F., et al. p53 mutations and aflatoxin B1 exposure in hepatocellular carcinoma patients from Thailand. International journal of cancer. Journal international du cancer. 1993;53:51–55.

Kirby G. M., Wolf C. R., Neal G. E., et al. In vitro metabolism of aflatoxin B1 by normal and tumorous liver tissue from Thailand. Carcinogenesis. 1993;14:2613–2620.

Maxuitenko Y. Y., MacMillan D. L., Kensler T. W., Roebuck B. D.. Evaluation of the post-initiation effects of oltipraz on aflatoxin B1-induced preneoplastic foci in a rat model of hepatic tumorigenesis. Carcinogenesis. 1993;14:2423–2425.

Gerbes A. L., Caselmann W. H.. Point mutations of the P53 gene, human hepatocellular carcinoma and aflatoxins. Journal of hepatology. 1993;19:312–315.

Olubuyide I. O., Maxwell S. M., Hood H., Neal G. E., Hendrickse R. G.. HBsAg, aflatoxins and primary hepatocellular carcinoma. African journal of medicine and medical sciences. 1993;22:89–91.

Hatch M. C., Chen C. J., Levin B., et al. Urinary aflatoxin levels, hepatitis-B virus infection and hepatocellular carcinoma in Taiwan. International journal of cancer. Journal international du cancer. 1993;54:931–934.

Wild C. P., Shrestha S. M., Anwar W. A., Montesano R.. Field studies of aflatoxin exposure, metabolism and induction of genetic alterations in relation to HBV infection and hepatocellular carcinoma in The Gambia and Thailand. Toxicology letters. 1992;64-65 Spec No:455–461.

Mehta R., Laver G. W., Stapley R., McMullen E.. Liver DNA adducts in methyl-deficient rats administered a single dose of aflatoxin B1. Carcinogenesis. 1992;13:1241–1247.

Hsia C. C., Kleiner D. E., Axiotis C. A., et al. Mutations of p53 gene in hepatocellular carcinoma: roles of hepatitis B virus and aflatoxin contamination in the diet. Journal of the National Cancer Institute. 1992;84:1638–1641.

Chen C. J., Zhang Y. J., Lu S. N., Santella R. M.. Aflatoxin B1 DNA adducts in smeared tumor tissue from patients with hepatocellular carcinoma. Hepatology (Baltimore, Md.). 1992;16:1150–1155.

Zhang M. D.. [Aflatoxins and primary liver cancer–a population based case-control study]. Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]. 1992;26:331–333.

Fujimoto Y., Hampton L. L., Luo L. D., Wirth P. J., Thorgeirsson S. S.. Low frequency of p53 gene mutation in tumors induced by aflatoxin B1 in nonhuman primates. Cancer research. 1992;52:1044–1046.

Yu S. Z.. [The aflatoxins and liver cancer in Guangxi, China]. Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]. 1992;26:162–164.

Zarba A., Hmieleski R., Hemenway D. R., Jakab G. J., Groopman J. D.. Aflatoxin B1–DNA adduct formation in rat liver following exposure by aerosol inhalation. Carcinogenesis. 1992;13:1031–1033.

Youngman L. D., Campbell T. C.. Inhibition of aflatoxin B1-induced gamma-glutamyltranspeptidase positive (GGT+) hepatic preneoplastic foci and tumors by low protein diets: evidence that altered GGT+ foci indicate neoplastic potential. Carcinogenesis. 1992;13:1607–1613.

Kolars J. C.. Aflatoxin and hepatocellular carcinoma: a useful paradigm for environmentally induced carcinogenesis. Hepatology (Baltimore, Md.). 1992;16:848–851.

Jennings G. S., Oesch F., Steinberg P.. In vivo formation of aflatoxin B1-DNA adducts in parenchymal and non-parenchymal cells of rat liver. Carcinogenesis. 1992;13:831–835.

Akao M., Kuroda K., Gonoi T., Kishikawa S.. Isolation of a metastasizing cancer cell line from an aflatoxin B1-induced rat liver tumor. Chemical & pharmaceutical bulletin. 1992;40:1299–1302.

Ross R. K., Yuan J. M., Yu M. C., et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet. 1992;339:943–946.

Wogan G. N.. Aflatoxins as risk factors for hepatocellular carcinoma in humans. Cancer research. 1992;52.

Mathur M., Rizvi T. A., Nayak N. C.. Aflatoxin B1 induced hepatocarcinogenesis in neonatal rats. Indian journal of experimental biology. 1992;30:165–168.

Hoseyni M. S.. Risk assessment for aflatoxin: III. Modeling the relative risk of hepatocellular carcinoma. Risk analysis : an official publication of the Society for Risk Analysis. 1992;12:123–128.

Lilleberg S. L., Cabonce M. A., Raju N. R., Wagner L. M., Kier L. D.. Alterations in the p53 tumor suppressor gene in rat liver tumors induced by aflatoxin B1. Progress in clinical and biological research. 1992;376:203–222.

Lilleberg S. L., Cabonce M. A., Raju N. R., Wagner L. M., Kier L. D.. Alterations in the structural gene and the expression of p53 in rat liver tumors induced by aflatoxin B1. Molecular carcinogenesis. 1992;6:159–172.

Kensler T. W., Groopman J. D., Eaton D. L., Curphey T. J., Roebuck B. D.. Potent inhibition of aflatoxin-induced hepatic tumorigenesis by the monofunctional enzyme inducer 1,2-dithiole-3-thione. Carcinogenesis. 1992;13:95–100.

Zhang Y. J., Chen C. J., Lee C. S., et al. Aflatoxin B1-DNA adducts and hepatitis B virus antigens in hepatocellular carcinoma and non-tumorous liver tissue. Carcinogenesis. 1991;12:2247–2252.

Srivatanakul P., Parkin D. M., Jiang Y. Z., et al. The role of infection by Opisthorchis viverrini, hepatitis B virus, and aflatoxin exposure in the etiology of liver cancer in Thailand. A correlation study. Cancer. 1991;68:2411–2417.

Sabbioni G., Wild C. P.. Identification of an aflatoxin G1-serum albumin adduct and its relevance to the measurement of human exposure to aflatoxins. Carcinogenesis. 1991;12:97–103.

Ozturk M.. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet. 1991;338:1356–1359.

Naidu N. R., Sehgal S., Bhaskar K. V., Aikat B. K.. Cystic disease of the liver following prenatal and perinatal exposure to aflatoxin B1 in rats. Journal of gastroenterology and hepatology. 1991;6:359–362.

Schlemper B., Harrison J., Garner R. C., Oesch F., Steinberg P.. DNA binding, adduct characterisation and metabolic activation of aflatoxin B1 catalysed by isolated rat liver parenchymal, Kupffer and endothelial cells. Archives of toxicology. 1991;65:633–639.

Zhang Y. J., Chen C. J., Haghighi B., et al. Quantitation of aflatoxin B1-DNA adducts in woodchuck hepatocytes and rat liver tissue by indirect immunofluorescence analysis. Cancer research. 1991;51:1720–1725.

Nunez O., Hendricks J. D., Duimstra J. R.. Ultrastructure of hepatocellular neoplasms in aflatoxin B1 (AFB1)-initiated rainbow trout (Oncorhynchus mykiss). Toxicologic pathology. 1991;19:11–23.

Chang Y. J., Mathews C., Mangold K., Marien K., Hendricks J., Bailey G.. Analysis of ras gene mutations in rainbow trout liver tumors initiated by aflatoxin B1. Molecular carcinogenesis. 1991;4:112–119.

Bonkovsky H. L.. Activation of the hepatocarcinogen aflatoxin B1 by forms of human hepatic cytochromes P-450: some do and some don’t. Hepatology (Baltimore, Md.). 1991;13:1003–1005.

Ueno Y., Kobayashi T., Yamamura H., et al. Effect of long-term feeding of nivalenol on aflatoxin B1-initiated hepatocarcinogenesis in mice. IARC scientific publications. 1991:420–423.

Liu Y. H., Taylor J., Linko P., Lucier G. W., Thompson C. L.. Glutathione S-transferase mu in human lymphocyte and liver: role in modulating formation of carcinogen-derived DNA adducts. Carcinogenesis. 1991;12:2269–2275.

Green J. A., Carthew P., Heuillet E., Simpson J. L., Manson M. M.. Cytokeratin expression during AFB1-induced carcinogenesis. Carcinogenesis. 1990;11:1175–1182.

Kraupp-Grasl B., Huber W., Putz B., Gerbracht U., Schulte-Hermann R.. Tumor promotion by the peroxisome proliferator nafenopin involving a specific subtype of altered foci in rat liver. Cancer research. 1990;50:3701–3708.

Buss P., Caviezel M., Lutz W. K.. Linear dose-response relationship for DNA adducts in rat liver from chronic exposure to aflatoxin B1. Carcinogenesis. 1990;11:2133–2135.

Corcos L., Rousset J. P., Kiefer F., Wiebel F. J., Weiss M. C.. Genetic analysis of aflatoxin B1 activation in rat hepatoma cells. Molecular & general genetics : MGG. 1990;222:291–296.

Rensburg S. J., Schalkwyk G. C., Schalkwyk D. J.. Primary liver cancer and aflatoxin intake in Transkei. Journal of environmental pathology, toxicology and oncology. 1990;10:11–16.

Morimura S., Tashiro F., Ueno Y.. Establishment and characterization of cell lines (Kagura-1 and Kagura-2) from aflatoxin B1-induced rat hepatoma. Chemical & pharmaceutical bulletin. 1990;38:460–463.

Cova L., Wild C. P., Mehrotra R., et al. Contribution of aflatoxin B1 and hepatitis B virus infection in the induction of liver tumors in ducks. Cancer research. 1990;50:2156–2163.

Cullen J. M., Marion P. L., Sherman G. J., Hong X., Newbold J. E.. Hepatic neoplasms in aflatoxin B1-treated, congenital duck hepatitis B virus-infected, and virus-free pekin ducks. Cancer research. 1990;50:4072–4080.

Angsubhakorn S., Get-Ngern P., Miyamoto M., Bhamarapravati N.. A single dose-response effect of aflatoxin B1 on rapid liver cancer induction in two strains of rats. International journal of cancer. Journal international du cancer. 1990;46:664–668.

Bauer-Hofmann R., Buchmann A., Wright A. S., Schwarz M.. Mutations in the Ha-ras proto-oncogene in spontaneous and chemically induced liver tumours of the CF1 mouse. Carcinogenesis. 1990;11:1875–1877.

Nixon M. W.. Aflatoxin and liver cancer. Lancet. 1990;335.

Lee H. S., Sarosi I., Vyas G. N.. Aflatoxin B1 formamidopyrimidine adducts in human hepatocarcinogenesis: a preliminary report. Gastroenterology. 1989;97:1281–1287.

Yan R. Q.. [A study on primary liver cancer in tree shrews induced by human hepatitis B virus and aflatoxin B1]. Zhonghua bing li xue za zhi Chinese journal of pathology. 1989;18:19–22.

Bechtel D. H.. Molecular dosimetry of hepatic aflatoxin B1-DNA adducts: linear correlation with hepatic cancer risk. Regulatory toxicology and pharmacology : RTP. 1989;10:74–81.

Baertschi S. W., Raney K. D., Shimada T., Harris T. M., Guengerich F. P.. Comparison of rates of enzymatic oxidation of aflatoxin B1, aflatoxin G1, and sterigmatocystin and activities of the epoxides in forming guanyl-N7 adducts and inducing different genetic responses. Chemical research in toxicology. 1989;2:114–112.

Bednarz W.. Primary and transplantable hepatomas induced by aflatoxin B1 in hypothyroid rats. Neoplasma. 1989;36:113–126.

Rizvi T. A., Mathur M., Nayak N. C.. Enhancement of aflatoxin B1-induced hepatocarcinogenesis in rats by partial hepatectomy. Virchows Archiv. B, Cell pathology including molecular pathology. 1989;56:345–350.

Black J. J., Maccubbin A. E., Myers H. K., Zeigel R. F.. Aflatoxin B1 induced hepatic neoplasia in Great Lakes coho salmon. Bulletin of environmental contamination and toxicology. 1988;41:742–745.

Bailey G. S., Williams D. E., Wilcox J. S., Loveland P. M., Coulombe R. A., Hendricks J. D.. Aflatoxin B1 carcinogenesis and its relation to DNA adduct formation and adduct persistence in sensitive and resistant salmonid fish. Carcinogenesis. 1988;9:1919–1926.

Lin C.. [An observation on hepatocarcinogenesis in rat by longterm feeding with minimal doses of aflatoxin B1]. Zhonghua bing li xue za zhi Chinese journal of pathology. 1988;17:198–200.

Corcos L., Weiss M. C.. Efficient one-step selection of hepatoma cell variants of a variety of phenotypes by use of aflatoxin B1. Differentiation; research in biological diversity. 1988;38:134–139.

Sinha S., Webber C., Marshall C. J., et al. Activation of ras oncogene in aflatoxin-induced rat liver carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America. 1988;85:3673–3677.

Cole K. E., Jones T. W., Lipsky M. M., Trump B. F., Hsu I. C.. In vitro binding of aflatoxin B1 and 2-acetylaminofluorene to rat, mouse and human hepatocyte DNA: the relationship of DNA binding to carcinogenicity. Carcinogenesis. 1988;9:711–716.

Soffritti M., McConnell E. E.. Liver foci formation during aflatoxin B1 carcinogenesis in the rat. Annals of the New York Academy of Sciences. 1988;534:531–540.

Angsubhakorn S., Bhamarapravati N., Sahaphong S., Sathiropas P.. Reducing effects of rodent malaria on hepatic carcinogenesis induced by dietary aflatoxin B1. International journal of cancer. Journal international du cancer. 1988;41:69–73.

Lohiya G., Nichols L., Hsieh D., Lohiya S., Nguyen H.. Aflatoxin content of foods served to a population with a high incidence of hepatocellular carcinoma. Hepatology (Baltimore, Md.). 1987;7:750–752.

Autrup H., Seremet T., Wakhisi J., Wasunna A.. Aflatoxin exposure measured by urinary excretion of aflatoxin B1-guanine adduct and hepatitis B virus infection in areas with different liver cancer incidence in Kenya. Cancer research. 1987;47:3430–3433.

Peers F., Bosch X., Kaldor J., Linsell A., Pluijmen M.. Aflatoxin exposure, hepatitis B virus infection and liver cancer in Swaziland. International journal of cancer. Journal international du cancer. 1987;39:545–553.

Stora C., Dvorackova I.. Aflatoxin, viral hepatitis and primary liver cancer. Journal of medicine. 1987;18:23–41.

Rajagopalan M. S., Busch M. P., Blum H. E., Vyas G. N.. Interaction of aflatoxin and hepatitis B virus in the pathogenesis of hepatocellular carcinoma. Life sciences. 1986;39:1287–1290.

Tashiro F., Morimura S., Hayashi K., et al. Expression of the c-Ha-ras and c-myc genes in aflatoxin B1-induced hepatocellular carcinomas. Biochemical and biophysical research communications. 1986;138:858–864.

Stora C., Dvorackova I.. [Respective roles of aflatoxin and hepatitis B in the etiology of primary cancer of the liver in man]. Bulletin de l’Académie nationale de médecine. 1986;170:763–775.

Nizami F., Nizami H. M., Ahmad M.. Urinary excretion of aflatoxin and liver cancer in Karachi. JPMA. The Journal of the Pakistan Medical Association. 1986;36:112–114.

Pironcheva G. L., Russev G. H.. New species of messenger RNA in aflatoxin B1 induced hepatocellular carcinoma. Cytobios. 1986;46:73–78.

Harries G. C., Boobis A. R., Collier N., Davies D. S.. Interindividual differences in the activation of two hepatic carcinogens to mutagens by human liver. Human toxicology. 1986;5:21–26.

McMahon G., Hanson L., Lee J. J., Wogan G. N.. Identification of an activated c-Ki-ras oncogene in rat liver tumors induced by aflatoxin B1. Proceedings of the National Academy of Sciences of the United States of America. 1986;83:9418–9422.

Appleton B. S.. Aflatoxin exposure and human liver-cancer risk. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 1985;23:129–130.

Sondergaard D., Taylor F., Newberne P. M.. Effects of the irreversible ornithine decarboxylase inhibitor, alpha-difluoromethylornithine, aflatoxin B1, and choline deficiency on hepatocarcinogenesis. Toxicologic pathology. 1985;13:36–49.

Van Rensburg S. J., Cook-Mozaffari P., Van Schalkwyk D. J., Watt J. J., Vincent T. J., Purchase I. F.. Hepatocellular carcinoma and dietary aflatoxin in Mozambique and Transkei. British journal of cancer. 1985;51:713–726.

Gallo M. A., Brooks L., McCoy J. R., Clark I.. Iron exclusion from aflatoxin B1-induced hepatocellular carcinoma in rats. Toxicology letters. 1985;27:1–6.

Sun T. T., Wu S. M., Wu Y. Y., Chu Y. R.. Measurement of individual aflatoxin exposure among people having different risk to primary hepatocellular carcinoma. Princess Takamatsu symposia. 1985;16:225–235.

Manson M. M., Green J. A., Neal G. E.. Monoclonal antibody against tumour-derived cell line shows heterogeneity of altered hepatocytes during AFB1-induced carcinogenesis. International journal of cancer. Journal international du cancer. 1984;34:869–874.

Daneshmend T. K.. Aflatoxin, hepatocellular carcinoma, and schistosomiasis. Lancet. 1984;2:1393–1394.

Hsieh D. P., Cullen J. M., Ruebner B. H.. Comparative hepatocarcinogenicity of aflatoxins B1 and M1 in the rat. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 1984;22:1027–1028.

Clawson G. A., Moody D. E., Ferrell L. D., Smuckler E. A.. Increased nucleoside triphosphatase activity of rat liver nuclear envelope is associated with hepatocarcinogen exposure. Laboratory investigation; a journal of technical methods and pathology. 1984;51:682–689.

Enwonwu C. O.. The role of dietary aflatoxin in the genesis of hepatocellular cancer in developing countries. Lancet. 1984;2:956–958.

Dichter C. R.. Risk estimates of liver cancer due to aflatoxin exposure from peanuts and peanut products. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 1984;22:431–437.

Bailey G. S., Taylor M. J., Loveland P. M., Wilcox J. S., Sinnhuber R. O., Selivonchick D. P.. Dietary modification of aflatoxin B1 carcinogenesis: mechanism studies with isolated hepatocytes from rainbow trout. National Cancer Institute monograph. 1984;65:379–385.

Dix K. M.. The development of hepatocellular tumours following aflatoxin B1 exposure of the partially hepatectomised mouse. Carcinogenesis. 1984;5:385–390.

Ayoola E. A.. Synergism between hepatitis B virus and aflatoxin in hepatocellular carcinoma. IARC scientific publications. 1984:167–179.

Stoloff L.. Aflatoxin as a cause of primary liver-cell cancer in the United States: a probability study. Nutrition and cancer. 1983;5:165–186.

Lin W., MacKenzie J. W., McCoy J. R., Clark I.. Metabolism of tRNA in rats with aflatoxin B1-induced hepatomas. Cancer biochemistry biophysics. 1983;7:61–68.

Wang Y. B., Lan L. Z., Ye B. F., Xu Y. C., Liu Y. Y., Li W. G.. Relation between geographical distribution of liver cancer and climate-aflatoxin B1 in China. Scientia Sinica. Series B, Chemical, biological, agricultural, medical & earth sciences / Chung-kuo k’o hsüeh yüan, chu pan. 1983;26:1166–1175.

Neal G. E., Legg R. F.. The ineffectiveness of reduced glutathione in preventing the development of liver tumours from aflatoxin-induced pre-neoplastic liver lesions. Cancer letters. 1983;21:83–87.

Gayda D. P., Pariza M. W.. Effects of carcinogens on hormonal regulation of gene expression in primary cultures of adult rat hepatocytes. Carcinogenesis. 1983;4:1127–1131.

Neal G. E., Green J. A.. The requirement for glutathione S-transferase in the conjugation of activated aflatoxin B1 during aflatoxin hepatocarcinogenesis in the rat. Chemico-biological interactions. 1983;45:259–275.

Novi A. M., Flörke R., Stukenkemper M.. Glutathione and aflatoxin-B1-induced liver tumors: requirement for an intact glutathione molecule for regression of malignancy in neoplastic tissue. Annals of the New York Academy of Sciences. 1982;397:62–71.

Huh N., Nemoto N., Utakoji T.. Metabolic activation of benzo[a]pyrene, aflatoxin B1, and dimethylnitrosamine by a human hepatoma cell line. Mutation research. 1982;94:339–348.

Loquet C., Wiebel F. J.. Geno- and cytotoxicity of nitrosamines, aflatoxin B1, and benzo[a]-pyrene in continuous cultures of rat hepatoma cells. Carcinogenesis. 1982;3:1213–1218.

Billings P. C., Uwaifo A. O., Heidelberger C.. Rat hepatoma cells show extreme sensitivity to aflatoxin B1. Toxicology and applied pharmacology. 1982;66:297–304.

Joishy S. K., Bennett J. M., Balasegaram M., et al. Clinical and chemotherapeutic study of hepatocellular carcinoma in Malaysia: a comparison with African and American patients. Cancer. 1982;50:1065–1069.

Clawson G. A., Smuckler E. A.. Increased amounts of double-stranded RNA in the cytoplasm of rat liver following treatment with carcinogens. Cancer research. 1982;42:3228–3231.

Bulatao-Jayme J., Almero E. M., Castro M. C., Jardeleza M. T., Salamat L. A.. A case-control dietary study of primary liver cancer risk from aflatoxin exposure. International journal of epidemiology. 1982;11:112–119.

Bhat N. K., Emeh J. K., Niranjan B. G., Avadhani N. G.. Inhibition of mitochondrial protein synthesis during early stages of aflatoxin B1-induced hepatocarcinogenesis. Cancer research. 1982;42:1876–1880.

Whitham M., Nixon J. E., Sinnhuber R. O.. Liver DNA bound in vivo with aflatoxin B1 as a measure of hepatocarcinoma initiation in rainbow trout. Journal of the National Cancer Institute. 1982;68:623–628.

Zhang F. S.. [Antigenic relationships between hepatitis type B and primary carcinoma of the liver]. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 1982;3:49–52.

Onyemelukwe G. C., Ogbadu G. H., Salifu A.. Aflatoxins, B1, B2, G1, G2 in primary liver cell carcinoma. Toxicology letters. 1982;10:309–312.

Niranjan B. G., Bhat N. K., Avadhani N. G.. Preferential attack of mitochondrial DNA by aflatoxin B1 during hepatocarcinogenesis. Science (New York, N.Y.). 1982;215:73–75.

McGlashan N. D.. Primary liver cancer and food-based toxins. A Swaziland review. Ecology of disease. 1982;1:37–44.

Woodhead A. D.. Biological characteristics of the aflatoxin-induced hepatic tumor. Basic life sciences. 1982;21:127–148.

Imaida K., Shirai T., Tatematsu M., Takano T., Ito N.. Dose responses of five hepatocarcinogens for the initiation of rat hepatocarcinogenesis. Cancer letters. 1981;14:279–283.

Angsubhakorn S., Bhamarapravati N., Romruen K., Sahaphong S.. Enhancing effects of dimethylnitrosamine on aflatoxin B hepatocarcinogenesis in rats. International journal of cancer. Journal international du cancer. 1981;28:621–626.

Wray B. B.. Aflatoxins, hepatitis B virus, and hepatocellular carcinoma. The New England journal of medicine. 1981;305.

Franco D., Morin J., Szekely A. M., Bismuth H.. Enhancement of Aflatoxin B1 induced liver carcinogenesis by portal diversion in the rat. Biomedicine / [publiée pour l’A.A.I.C.I.G.]. 1981;35:162–165.

Nixon J. E., Hendricks J. D., Pawloswki N. E., Loveland P. M., Sinnhuber R. O.. Carcinogenicity of aflatoxicol in Fischer 344 rats. Journal of the National Cancer Institute. 1981;66:1159–1163.

Butler W. H., Hempsall V.. Histochemical studies of hepatocellular carcinomas in the rat induced by aflatoxin. The Journal of pathology. 1981;134:157–170.

Novi A. M.. Regression of aflatoxin B1-induced hepatocellular carcinomas by reduced glutathione. Science (New York, N.Y.). 1981;212:541–542.

Croy R. G., Wogan G. N.. Quantitative comparison of covalent aflatoxin-DNA adducts formed in rat and mouse livers and kidneys. Journal of the National Cancer Institute. 1981;66:761–768.

Schoenhard G. L., Hendricks J. D., Nixon J. E., et al. Aflatoxicol-induced hepatocellular carcinoma in rainbow trout (Salmo gairdneri) and the synergistic effects of cyclopropenoid fatty acids. Cancer research. 1981;41:1011–1014.

Croy R. G., Wogan G. N.. Temporal patterns of covalent DNA adducts in rat liver after single and multiple doses of aflatoxin B1. Cancer research. 1981;41:197–203.

Neal G. E., Metcalfe S. A., Legg R. F., Judah D. H., Green J. A.. Mechanism of the resistance to cytotoxicity which precedes aflatoxin B1 hepatocarcinogenesis. Carcinogenesis. 1981;2:457–461.

Stora C., Dvorackova I., Ayraud N.. Characterization of aflatoxin BI (AFB) in human liver cancer. Research communications in chemical pathology and pharmacology. 1981;31:77–84.

Gasiorowski K., Zawirska B.. Cytophotometric and cytogenetic characteristics of primary hepatomas induced in Wistar rats by aflatoxin B1. Neoplasma. 1981;28:151–157.

Emeh J. K., Niranjan B. G., Bhat N. K., Avadhani N. G.. Modulation of hepatic transcription and translation during early stages of aflatoxin B1 carcinogenesis. Carcinogenesis. 1981;2:373–378.

Zawirska B., Bednarz W.. The particular traits of carcinogenesis induced in Wistar rats by aflatoxin B1. III. Porphyrins and the activity of gamma-glutamyltranspeptidase in primary hepatomas and in their tissue of origin. Neoplasma. 1981;28:35–49.

Linsell A.. Incidence of hepato-carcinoma in relation to aflatoxin intake. Archives of toxicology. Supplement. = Archiv für Toxikologie. Supplement. 1980;3:13–18.

Lambiotte M., Thierry N.. Glucocorticoid enhancement of aflatoxin B1 cytotoxicity in differentiated rat hepatoma cultures. Annals of the New York Academy of Sciences. 1980;349:401–403.

Essigmann J. M., Donahue P. R., Story D. L., Wogan G. N., Brunengraber H.. Use of the isolated perfused rat liver to study carcinogen-DNA adduct formation from aflatoxin B1 and sterigmatocystin. Cancer research. 1980;40:4085–4091.

Chedid A., Halfman C. J., Greenberg S. R.. Hormonal influences on chemical carcinogenesis: studies with the aflatoxin B1 hepatocarcinoma model in the rat. Digestive diseases and sciences. 1980;25:869–874.

Bednarz W., Borowiec J., Izbicki T., Markuszewska-Bednarz I. J.. [Hormonally determined growth of transplantable hepatoma induced by aflatoxin B1 in Wistar rats]. Patologia polska. 1980;31:505–517.

Onyemelukwe C. G., Nirodi C., West C. E.. Aflatoxin B1 in hepatocellular carcinoma. Tropical and geographical medicine. 1980;32:237–240.

Wray B. B., Hayes A. W.. Aflatoxin B1 in the serum of a patient with primary hepatic carcinoma. Environmental research. 1980;22:400–403.

Sieber S. M., Correa P., Dalgard D. W., Adamson R. H.. Induction of osteogenic sarcomas and tumors of the hepatobiliary system in nonhuman primates with aflatoxin B1. Cancer research. 1979;39:4545–4554.

Lambiotte M., Thierry N.. Enhancement of aflatoxin B1 cytotoxicity in differentiated rat hepatoma cultures by a prior glucocorticoid treatment of the monolayer. Biochemical and biophysical research communications. 1979;89:933–942.

Zawirska B.. [Selected characteristics of carcinogenesis induced in Wistar rats by aflatoxin B1. II. Porphyrin metabolism at different phases of hepatocarcinogenesis]. Patologia polska. 1979;30:457–474.

Stora C., Aussel C., Mayzaud O., Masseyeff R.. Hepatocarcinogenesis by aflatoxin B1: relationships between the cellular localization of the carcinogen and early histological changes in the rat liver. Biomedicine / [publiée pour l’A.A.I.C.I.G.]. 1979;31:173–176.

Wong Z. A., Decad G. M., Byard J. L., Hsieh D. P.. Conversion of aflatoxicol to aflatoxin B1 in rats in vivo and in primary hepatocyte culture. Food and cosmetics toxicology. 1979;17:481–486.

Newberne P. M., Weigert J., Kula N.. Effects of dietary fat on hepatic mixed-function oxidases and hepatocellular carcinoma induced by aflatoxin B1 in rats. Cancer research. 1979;39:3986–3991.

Lutwick L. I.. Relation between aflatoxin, hepatitis-B virus, and hepatocellular carcinoma. Lancet. 1979;1:755–757.

Young R., Porter J. H.. Effects of the hepatocarcinogen, aflatoxin, on open-field behaviors in Syrian hamsters. Behavioral biology. 1978;23:536–542.

Schaeffer W. I., Heintz N. H.. A diploid rat liver cell culture. IV. Malignant transformation by aflatoxin B1. In vitro. 1978;14:418–427.

Croy R. G., Essigmann J. M., Reinhold V. N., Wogan G. N.. Identification of the principal aflatoxin B1-DNA adduct formed in vivo in rat liver. Proceedings of the National Academy of Sciences of the United States of America. 1978;75:1745–1749.

Novi A. M.. [Diffuse distribution of proliferative changes in the rat liver during aflatoxin B carcinogenesis–based on a quantitative histological study]. Verhandlungen der Deutschen Gesellschaft für Pathologie. 1978;62.

Fahmy M. J., Fahmy O. G., Swenson D. H.. Aflatoxin B1-2,3-dichloride as a model of the active metabolite of aflatoxin B1 in mutagenesis and carcinogenesis. Cancer research. 1978;38:2608–2616.

Wales J. H., Sinnhuber R. O., Hendricks J. D., Nixon J. E., Eisele T. A.. Aflatoxin B1 induction of hepatocellular carcinoma in the embryos of rainbow trout (Salmo gairdneri). Journal of the National Cancer Institute. 1978;60:1133–1139.

Stora C.. [Aflatoxin is present in primary liver cancers in residents of Zaïre]. Comptes rendus hebdomadaires des séances de l’Académie des sciences. Série D: Sciences naturelles. 1978;286:917–920.

Sarasin A., Goze A., Devoret R., Moulé Y.. Induced reactivity of UV-damaged phage gamma in E. coli K12 host cells treated with aflatoxin B1 metabolites. Mutation research. 1977;42:205–214.

Novi A. M.. Liver carcinogenesis in rats after aflatoxin B1 administration. A light- and electron-microscopic study. Current topics in pathology. Ergebnisse der Pathologie. 1977;65:115–163.

Peers F. G., Linsell C. A.. Dietary aflatoxins and human primary liver cancer. Annales de la nutrition et de l’alimentation. 1977;31:1005–1017.

Linsell C. A., Peers F. G.. Aflatoxin and liver cell cancer. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1977;71:471–473.

Mainigi K. D., Sorof S.. Carcinogen-protein complexes in liver during hepatocarcinogenesis by aflatoxin B1(1). Cancer research. 1977;37:4304–4312.

Aflatoxin and liver cancer. JPMA. The Journal of the Pakistan Medical Association. 1977;27.

Nishizumi M., Albert R. E., Burns F. J., Bilger L.. Hepatic cell loss and proliferation induced by N-2-fluorenylacetamide, diethylnitrosamine, and aflatoxin B1 in relation to hepatoma induction. British journal of cancer. 1977;36:192–197.

Nizami H. M., Zuberi S. J.. Aflatoxin and liver cancer in Karachi, a preliminary survey. JPMA. The Journal of the Pakistan Medical Association. 1977;27:351–352.

Scarpelli D. G.. Drug metabolism and aflatoxin-induced hepatoma in rainbow trout (Salmo gairdneri). Progress in experimental tumor research. 1976;20:339–350.

Adamson R. H., Correa P., Sieber S. M., McIntire K. R., Dalgard D. W.. Carcinogenicity of aflatoxin B1 in rhesus monkeys: two additional cases of primary liver cancer. Journal of the National Cancer Institute. 1976;57:67–78.

Busby W. F., Paglialunga S., Newberne P. M., Wogan G. N.. Transfer RNA methylase activity and capacity during aflatoxin B1-induced hepatocellular carcinogenesis. Cancer research. 1976;36:2013–2018.

Peers F. G., Gilman G. A., Linsell C. A.. Dietary aflatoxins and human liver cancer. A study in Swaziland. International journal of cancer. Journal international du cancer. 1976;17:167–176.

Gurtoo H. L., Motycka L. E., Parker N. B.. Sex dependence of the metabolic activation in vitro of the mycohepatocarcinogen aflatoxin B1. Journal of medicine. 1976;7:1–12.

Reddy J. K., Svoboda D. J., Rao M. S.. Induction of liver tumors by aflatoxin B1 in the tree shrew (Tupaia glis), a nonhuman primate. Cancer research. 1976;36:151–160.

Wogan G. N.. Dietary factors and special epidemiological situations of liver cancer in Thailand and Africa. Cancer research. 1975;35:3499–3502.

Kalengayi M. M., Desmet V. J.. Sequential histological and histochemical study of the rat liver during aflatoxin B1-induced carcinogenesis. Cancer research. 1975;35:2845–2852.

Letter: The aflatoxin-hepatoma-HBAg story. British medical journal. 1975;3:592–593.

Kalengayi M. M., Ronchi G., Desmet V. J.. Histochemistry of gamma-glutamyl transpeptidase in rat liver during aflatoxin B1-induced carcinogenesis. Journal of the National Cancer Institute. 1975;55:579–588.

Editorial: More on the aflatoxin-hepatoma story. British medical journal. 1975;2:647–648.

Bagshawe A. F., Gacengi D. M., Cameron C. H., Dorman J., Dane D. S.. Hepatitis Bs antigen and liver cancer: A population based study in Kenya. British journal of cancer. 1975;31:581–584.

Kroes R., Sontag J. M., Sell S., Williams G. M., Weisburger J. H.. Elevated concentrations of serum alpha-fetoprotein in rats with chemically induced liver tumors. Cancer research. 1975;35:1214–1217.

Tilak T. B.. Induction of cholangiocarcinoma following treatment of a rhesus monkey with aflatoxin. Food and cosmetics toxicology. 1975;13:247–249.

Payet M.. [Aflatoxins and cancer of the liver]. Médecine & chirurgie digestives. 1975;4 suppl 2.

Van Rensburg S. J., Watt J. J., Purchase I. F., Pereira Coutinho L., Markham R.. Primary liver cancer rate and aflatoxin intake in a high cancer area. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. 1974;48.

Aflatoxin and primary liver cancer. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. 1974;48:2495–2496.

Sinnhuber R. O., Lee D. J., Wales J. H., Landers M. K., Keyl A. C.. Hepatic carcinogenesis of aflatoxin M1 in rainbow trout (Salmo gairdneri) and its enchancement by cyclopropene fatty acids. Journal of the National Cancer Institute. 1974;53:1285–1288.

Campbell T. C., Sinnhuber R. O., Lee D. J., Wales J. H., Salamat L.. Hepatocarcinogenic material in urine specimens from humans consuming aflatoxin. Journal of the National Cancer Institute. 1974;52:1647–1649.

Sen S.. Aflatoxin hepatic carcinogenesis (sequential study in albino rats). Journal of the Indian Medical Association. 1974;62:75–78.

Schwartz A. G.. Protective effect of benzoflavone and estrogen against 7,12-dimethylbenz(a)anthracene- and aflatoxin-induced cytotoxicity in cultured liver cells. Cancer research. 1974;34:10–15.

Pokrovskiĭ A. A., Nikolaeva M. Ia a., Lashneva N. V., Kravchenko L. V., Korovnikov K. A.. [Liver enzymes in precarcinogenesis caused by aflatoxin]. Voprosy onkologii. 1974;20:75–79.

Bausher J., Schaeffer W. I.. A diploid rat liver cell culture. 1. Characterization and sensitivity to aflatoxin B1. In vitro. 1974;9:286–293.

Newberne P. M., Rogers A. E.. Animal model of human disease: primary hepatocellular carcinoma. The American journal of pathology. 1973;72:137–140.

Peers F. G., Linsell C. A.. Dietary aflatoxins and liver cancer–a population based study in Kenya. British journal of cancer. 1973;27:473–484.

Swenson D. H., Miller J. A., Miller E. C.. 2,3-Dihydro-2,3-dihydroxy-aflatoxin B1: an acid hydrolysis product of an RNA-aflatoxin B1 adduct formed by hamster and rat liver microsomes in vitro. Biochemical and biophysical research communications. 1973;53:1260–1267.

Pitout M. J., Watt J. J., Kempff P. G., Dijkstra J., Schabort J. C.. The effects of aflatoxin B 1 and aminoazodye carcinogens on rat and mouse liver nuclear acid deoxyribonuclease. Chemico-biological interactions. 1973;6:227–235.

Bassir O., Emerole B. O.. Comparative oxidative metabolism of aflatoxin B1 and palmotoxins B0 and G0 by rat liver microsomal fractions. Xenobiotica; the fate of foreign compounds in biological systems. 1973;3:201–205.

Sato S., Matsushima T., Tanaka N., Sugimura T., Takashima F.. Hepatic tumors in the guppy (Lebistes reticulatus) induced by aflatoxin B 1 , dimethylintrosamine, and 2-acetylaminofluorene. Journal of the National Cancer Institute. 1973;50:767–778.

Williams G. M., Elliott J. M., Weisburger J. H.. Carcinoma after malignant conversion in vitro of epithelial-like cells from rat liver following exposure to chemical carcinogens. Cancer research. 1973;33:606–612.

Adamson R. H., Correa P., Dalgard D. W.. Occurrence of a primary liver carcinoma in a Rhesus monkey fed aflatoxin B 1 . Journal of the National Cancer Institute. 1973;50:549–553.

Cardeilhac P. T., Nair K. P.. Inhibition by castration of aflatoxin-induced hepatoma in carbon tetrachloride-treated rats. Toxicology and applied pharmacology. 1973;26:393–397.

Kores R. M., Sontag J. M., Weisburger J. H., Newberne P. M., Wogan G. N.. -Foetoprotein in rats with hepatomas induced by aflatoxin B 1 . Nature. 1972;240:240–241.

Vesselinovitch S. D., Mihailovich N., Wogan G. N., Lombard L. S., Rao K. V.. Aflatoxin B 1 , a hepatocarcinogen in the infant mouse. Cancer research. 1972;32:2289–2291.

Sen S.. Aflatoxin hepatic carcinogenesis: an experimental comparative study. The Indian journal of medical research. 1972;60:1261–1266.

Gopalan C., Tulpule P. G., Krishnamurthi D.. Induction of hepatic carcinoma with aflatoxin in the rhesus monkey. Food and cosmetics toxicology. 1972;10:519–521.

Horton B. J., Horton J. D., Sabine J. R.. Metabolic controls in precancerous liver. II. Loss of feedback control of cholesterol synthesis, measured repeatedly in vivo, during treatment with the carcinogens N-2-fluorenylacetamide and aflatoxin. European journal of cancer. 1972;8:437–443.

Wales J. H., Sinnhuber R. O.. Hepatomas induced by aflatoxin in the sockeye salmon (Oncorhynchus nerka). Journal of the National Cancer Institute. 1972;48:1529–1530.

Shank R. C., Siddhichai P., Subhamani B., Bhamarapravati N., Gordon J. E., Wogan G. N.. Dietary aflatoxins and human liver cancer. V. Duration of primary liver cancer and prevalence of hepatomegaly in Thailand. Food and cosmetics toxicology. 1972;10:181–191.

Shank R. C., Bhamarapravati N., Gordon J. E., Wogan G. N.. Dietary aflatoxins and human liver cancer. IV. Incidence of primary liver cancer in two municipal populations of Thailand. Food and cosmetics toxicology. 1972;10:171–179.

Reddy J. K., Svoboda D.. Effect of lasiocarpine on aflatoxin B 1 carcinogenicity in rat liver. Archives of pathology. 1972;93:55–60.

Linsell C. A., Peers F. G.. The aflatoxins and human liver cancer. Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer. 1972;39:125–129.

Cruickshank A. H., Sparshott S. M.. Malignancy in natural and experimental hepatic cysts: experiments with aflatoxin in rats and the malignant transformation of cysts in human livers. The Journal of pathology. 1971;104:185–190.

Alpert M. E., Hutt M. S., Wogan G. N., Davidson C. S.. Association between aflatoxin content of food and hepatoma frequency in Uganda. Cancer. 1971;28:253–260.

Sun S. C., Wei R. D., Schaeffer B. T.. The influence of postnecrotic cirrhosis on aflatoxin carcinogenesis in rats. Laboratory investigation; a journal of technical methods and pathology. 1971;24:368–372.

Rogers A. E., Kula N. S., Newberne P. M.. Absence of an effect of partial hepatectomy on aflatoxin B 1 carcinogenesis. Cancer research. 1971;31:491–495.

Keen P., Martin P.. Is aflatoxin carcinogenic in man? The evidence in Swaziland. Tropical and geographical medicine. 1971;23:44–53.

Lee D. J., Wales J. H., Sinnhuber R. O.. Promotion of aflatoxin-induced hepatoma growth in trout by methyl malvalate and sterculate. Cancer research. 1971;31:960–963.

Ayres J. L., Lee D. J., Wales J. H., Sinnhuber R. O.. Aflatoxin structure and hepatocarcinogenicity in rainbow trout (Salmo gairdneri). Journal of the National Cancer Institute. 1971;46:561–564.

Le Breton E.. [Hepatic cancer and mycotoxins]. Annales de biologie clinique. 1970;28:203–208.

Schoental R.. Hepatotoxic activity of retrorsine, senkirkine and hydroxysenkirkine in newborn rats, and the role of epoxides in carcinogenesis by pyrrolizidine alkaloids and aflatoxins. Nature. 1970;227:401–402.

Lafarge C., Frayssinet C.. The reversibility of inhibition of RNA and DNA synthesis induced by aflatoxin in rat liver. A tentative explanation for carcinogenic mechanism. International journal of cancer. Journal international du cancer. 1970;6:74–83.

Friedman M. A., Wogan G. N.. Liver nuclear RNA metabolism in rats treated with aflatoxin B1. Life sciences. Pt. 2: Biochemistry, general and molecular biology. 1970;9:741–747.

Guimarães J. P., Kerr I. B., Cardoso H.. [Findings of aflatoxins in food rations and hepatoma incidence in mice]. Hospital (Rio de Janeiro, Brazil). 1970;77:583–585.

Goodall C. M., Butler W. H.. Aflatoxin carcinogenesis: inhibition of liver cancer induction in hypophysectomized rats. International journal of cancer. Journal international du cancer. 1969;4:422–429.

Wunder W., Otto H.. [Aflatoxin as cause of liver cancer in trout]. Die Naturwissenschaften. 1969;56:352–355.

Alpert M. E., Davidson C. S.. Mycotoxins. A possible cause of primary carcinoma of the liver. The American journal of medicine. 1969;46:325–329.

Codegone M. L., Provana A., Ghittino P., Palestro G.. [Experimental study of the action of some carcinogens on the trout liver]. Il Cancro. 1968;21:469–476.

Sinnhuber R. O., Lee D. J., Wales J. H., Ayres J. L.. Dietary factors and hepatoma in rainbow trout (Salmo gairdneri). II. Cocarcinogenes by cyclopropenoid fatty acids and the effect of gossypol and altered lipids on aflatoxin-induced liver cancer. Journal of the National Cancer Institute. 1968;41:1293–1301.

Lancaster M. C.. Comparative aspects of aflatoxin-induced hepatic tumors. Cancer research. 1968;28:2288–2292.

Sinnhuber R. O., Wales J. H., Ayres J. L., Engebrecht R. H., Amend D. L.. Dietary factors and hepatoma in rainbow trout (Salmo gairdneri). I. Aflatoxins in vegetable protein feedstuffs. Journal of the National Cancer Institute. 1968;41:711–718.

Korobkin M., Williams E. H.. Hepatoma and groundnuts in the West Nile district of Uganda. The Yale journal of biology and medicine. 1968;41:69–78.

Halver J. E.. Aflatoxicosis and trout hepatoma. Bulletin – Office international des épizooties. 1968;69:1249–1278.

Jackson E. W., Wolf H., Sinnhuber R. O.. The relationship of hepatoma in rainbow trout to aflatoxin contamination and cottonseed meal. Cancer research. 1968;28:987–991.

Ghittino P., Codegone M. L., Provana A.. [Periods of administration of aflatoxin-containing diet and hepatoma in the rainbow trout]. Il Cancro. 1968;21:619–627.

Carnaghan R. B.. Hepatic tumours and other chronic liver changes in rats following a single oral administration of aflatoxin. British journal of cancer. 1967;21:811–814.

Unuma T., Morris H. P., Busch H.. Comparative studies of the nucleoli of Morris hepatomas, embryonic liver, and aflatoxin B1-treated liver of rats. Cancer research. 1967;27:2221–2233.

Purchase I. F.. Fungal metabolites as potential carcinogens, with particular reference to their role in the aetiology of hepatoma. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. 1967;41:406–413.

Richir C., Cros J., Toury J., Quenum C., Dupin H. (Apropos of a metastasizing hepatoma occurring in a Wistar rat subjected o a diet containing aflatoxin). Nutritio et dieta; European review of nutrition and dietetics. 1964;6.